<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methylprednisolone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methylprednisolone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methylprednisolone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9639" href="/d/html/9639.html" rel="external">see "Methylprednisolone: Drug information"</a> and <a class="drug drug_patient" data-topicid="11181" href="/d/html/11181.html" rel="external">see "Methylprednisolone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F195382"><span class="drugH1">Brand Names: US</span>
<ul>
<li>DEPO-Medrol;</li>
<li>Medrol;</li>
<li>P-Care D40 [DSC];</li>
<li>P-Care D80 [DSC];</li>
<li>SOLU-Medrol</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867534"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Depo-Medrol;</li>
<li>Medrol;</li>
<li>Solu-MEDROL;</li>
<li>SOLU-Medrol (PF);</li>
<li>Uni-Med [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1053999"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenal Corticosteroid</span>;</li>
<li>
<span class="list-set-name">Anti-inflammatory Agent</span>;</li>
<li>
<span class="list-set-name">Antiasthmatic</span>;</li>
<li>
<span class="list-set-name">Corticosteroid, Systemic</span>;</li>
<li>
<span class="list-set-name">Glucocorticoid</span></li></ul></div>
<div class="block dop drugH1Div" id="F195409"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Only the methylprednisolone <b>succinate</b> formulation (Solu-Medrol) may be given IV. Methylprednisolone <b>acetate</b> suspension (Depo-Medrol) is intended for IM or intra-articular administration only; do <b>not</b> administer the acetate preparation IV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grissinger.1','lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grissinger.1','lexi-content-ref-ISMP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Adjust dose depending upon condition being treated and response of patient. Individualize dosing and use the lowest possible dose to control the condition; when dose reduction is possible, reduce dose gradually.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General</b>
<b> dosing; anti-inflammatory or immunosuppressive</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Methylprednisolone sodium <b>succinate (immediate acting)</b>:</i> Infants, Children, and Adolescents: Oral, IV, IM: 0.11 to 1.6 mg/kg/<b>day</b> in 3 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Methylprednisolone <b>acetate (long acting)</b>:</i> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IM: 0.11 to 1.6 mg/kg/dose; frequency depends upon condition being treated, usually administered as a one-time dose or every 1 to 2 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Intra-articular: Dosing varies based on affected joint; general range: 4 to 80 mg every 1 to 5 weeks.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9af55968-d11e-416a-9414-dc082d90b3f0">Anaphylaxis, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaphylaxis, adjunctive therapy:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Administer epinephrine first when treating anaphylaxis. Corticosteroids are considered second- or third-line therapy and do not result in prompt resolution of airway obstruction or shock. Use of corticosteroids for anaphylaxis is controversial; they have little to no benefit on initial symptoms; typically administered to prevent biphasic or prolonged episodes of anaphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-32001253','lexi-content-ref-24909803','lexi-content-ref-33204386','lexi-content-ref-23268454','lexi-content-ref-26525001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-32001253','lexi-content-ref-24909803','lexi-content-ref-33204386','lexi-content-ref-23268454','lexi-content-ref-26525001'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV, IM (succinate): 1 to 2 mg/kg/dose as a single dose; maximum dose: 125 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-23268454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-23268454'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c809d59-12de-4789-a830-b048cd9fbce6">Asthma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acute exacerbation: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Outpatient management</i>
<i> (short-course "burst") (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Oral: <b>Note:</b> Burst should be continued until symptoms resolve or patient achieves peak expiratory flow 80% of personal best; usually requires 3 to 10 days of treatment (~5 days on average); longer treatment may be required.</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children &lt;12 years: Oral: 1 to 2 mg/kg/<b>day</b> in 1 or 2 divided doses for 3 to 10 days; maximum daily dose: 60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: Oral: 40 to 60 mg/<b>day</b> in 1 or 2 divided doses for 3 to 10 days.</p>
<p style="text-indent:-2em;margin-left:8em;">IM (acetate): <b>Note:</b> This may be given in place of short-course "burst" of oral steroids in patients who are vomiting or if compliance is a problem.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≤4 years: IM: 7.5 mg/kg as a one-time dose; maximum dose: 240 mg.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥5 years and Adolescents: IM: 240 mg as a one-time dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Emergency/acute care management:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children &lt;12 years: Oral, IV (succinate): 1 to 2 mg/kg/<b>day</b> in 2 divided doses; maximum daily dose: 60 mg/<b>day</b>; continue until peak expiratory flow is 70% of predicted or personal best (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>). Some experts suggest infants and children ≤5 years may receive IV doses of 1 mg/kg/dose every 6 hours on day 1, followed by transition to oral corticosteroids to complete a 3 to 5 days course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral, IV (succinate): 40 to 80 mg/<b>day</b> in 1 or 2 divided doses until peak expiratory flow is 70% of predicted or personal best (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Status asthmaticus:</i> Children and Adolescents: IV (succinate): Loading dose: 2 mg/kg/dose, then 0.5 to 1 mg/kg/dose every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23537669','lexi-content-ref-23628833','lexi-content-ref-3302924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23537669','lexi-content-ref-23628833','lexi-content-ref-3302924'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Long-term treatment (non-acute), severe, persistent asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;12 years: Oral: 0.25 to 2 mg/kg/<b>day</b> once daily in the morning or every other day as needed for asthma control; maximum daily dose: 60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Oral: 7.5 to 60 mg once daily in the morning or every other day as needed for asthma control.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59e38d44-f7f8-46cb-81e2-809dd0575e0c">Graft-versus-host disease, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, acute (GVHD):</b> Limited data available: Infants, Children, and Adolescents: IV (succinate): 1 to 2 mg/kg/dose once daily; if using low dose (1 mg/kg) and no improvement after 3 days, increase dose to 2 mg/kg. Continue therapy for 5 to 7 days; if improvement observed, may taper by 10% of starting dose every 4 days; if no improvement, then considered steroid-refractory GVHD and additional agents should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20307721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20307721'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31e74d58-0537-4d15-91f2-16c039a00a3f">Immune thrombocytopenia, moderate to severe bleeding or at risk for severe bleeding</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia, moderate to severe bleeding or at risk for severe bleeding:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV (succinate): Initial: Pulse: 30 mg/kg/dose once daily for 1 to 3 doses; number of doses is determined by patient clinical status, initial and postdose platelet counts, and if used in conjunction with other therapies; maximum dose: 1,000 mg/dose; follow with oral corticosteroid therapy as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12368690','lexi-content-ref-10761200','lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12368690','lexi-content-ref-10761200','lexi-content-ref-31770441'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35d2d51d-1880-43c6-89eb-39ca0b09eb95">Juvenile idiopathic arthritis, systemic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis, systemic: Note:</b> Therapy should be individualized based on disease severity and activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22290637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22290637'])">Ref</a></span>). Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: IV (succinate): Pulse therapy: 30 mg/kg/<b>day</b> once daily for 3 days; maximum dose: 1,000 mg/dose. Follow pulse therapy with oral corticosteroids; evaluate initial response at 1 to 2 weeks and then at 1 month of therapy; if condition worsens or unchanged at either time interval, may repeat methylprednisolone 30 mg/kg/dose at weekly intervals as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22290637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22290637'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="adf7ca0a-2a24-4930-8afc-95146096439c">Kawasaki disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kawasaki disease:</b> Limited data available; optimal regimen not established; efficacy variable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary adjunctive treatment, patients at high risk for intravenous immune globulin (IVIG) resistance or</i>
<i>coronary artery aneurysms: </i>
<b>Note: </b>Use in combination with IVIG and aspirin:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: IV (succinate): 1.6 mg/kg/<b>day</b> in divided doses every 8 hours for 5 days or until afebrile, then transition to oral prednisolone; maximum daily dose: 48 mg/<b>day; </b>some centers use less frequent dosing intervals (eg, every 12 hours) to minimize adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356445','lexi-content-ref-22405251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356445','lexi-content-ref-22405251'])">Ref</a></span>). <b>Note:</b> Dosing based on use of IV prednisolone product (2 mg/kg/day), which is not available in the United States; dosing converted to equivalent methylprednisolone dosing; however, clinical necessity of conversion is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, refractory/resistant disease: </i>
<b>Note:</b> Reserve use for patients who remain febrile after initial IVIG dose:</p>
<p style="text-indent:-2em;margin-left:6em;">Pulse dosing: Infants and Children: IV (succinate): 30 mg/kg/dose once daily for 1 or 3 days; may be given in combination with additional IVIG dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356445','lexi-content-ref-29173297','lexi-content-ref-18175148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356445','lexi-content-ref-29173297','lexi-content-ref-18175148'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Taper dosing: Infants and Children: IV (succinate): 1.6 mg/kg/<b>day</b> in divided doses every 8 hours for 5 days or until afebrile, then transition to oral prednisolone; maximum daily dose: 48 mg/<b>day</b>; give in combination with aspirin and an additional dose of IVIG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356445','lexi-content-ref-22405251','lexi-content-ref-23485027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356445','lexi-content-ref-22405251','lexi-content-ref-23485027'])">Ref</a></span>). <b>Note:</b> Dosing based on use of IV prednisolone product (2 mg/kg/day) which is not available in the United States; dosing converted to equivalent methylprednisolone dosing; however, clinical necessity of conversion is unknown.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65d2ea53-b01d-480b-b7db-288a7bfc19bc">Lupus nephritis, proliferative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lupus nephritis, proliferative (induction):</b> Limited data available: Children and Adolescents: IV (succinate): Initial pulse therapy: 30 mg/kg/dose once daily for 3 doses; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22162255','lexi-content-ref-34279063','lexi-content-ref-32220834','lexi-content-ref-28877866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22162255','lexi-content-ref-34279063','lexi-content-ref-32220834','lexi-content-ref-28877866'])">Ref</a></span>). Reported dosage range: 10 to 30 mg/kg/dose <b>or </b>500 to 1,000 mg/<b>m<sup>2</sup></b>/dose once daily for 3 days. Following pulse therapy transition to oral corticosteroids and taper as clinically indicated. May be given as part of an appropriate combination dosage regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16827597','lexi-content-ref-20581019','lexi-content-ref-28191596','lexi-content-ref-34279063','lexi-content-ref-28780657','lexi-content-ref-20222881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16827597','lexi-content-ref-20581019','lexi-content-ref-28191596','lexi-content-ref-34279063','lexi-content-ref-28780657','lexi-content-ref-20222881'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2409ba83-3fab-48ac-bd75-41b00b70b569">Multisystem inflammatory syndrome in children associated with SARS-CoV-2</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial therapy</i>: IV (succinate): 1 to 2 mg/kg/<b>day</b> divided twice daily in combination with IVIG; duration is dependent on clinical course; may then transition to oral steroids, with taper over at least 2 to 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1','lexi-content-ref-33557873','lexi-content-ref-33211859','lexi-content-ref-33003176','lexi-content-ref-NIH.1','lexi-content-ref-33523115','lexi-content-ref-34133855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1','lexi-content-ref-33557873','lexi-content-ref-33211859','lexi-content-ref-33003176','lexi-content-ref-NIH.1','lexi-content-ref-33523115','lexi-content-ref-34133855'])">Ref</a></span>). <b>Note:</b> High-dose corticosteroid therapy at doses of 10 to 30 mg/kg/day (maximum dose: 1,000 mg/dose) for 1 to 3 days has also been reported as initial therapy of MIS-C in patients with more severe disease (eg, shock symptoms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-33557873','lexi-content-ref-32463092','lexi-content-ref-33211859','lexi-content-ref-33003176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-33557873','lexi-content-ref-32463092','lexi-content-ref-33211859','lexi-content-ref-33003176'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intensification therapy</i> (in patients who do not improve within 24 hours of initial MIS-C therapy with low- to moderate-dose corticosteroid therapy and IVIG): IV (succinate): 10 to 30 mg/kg/<b>day</b> (maximum dose: 1,000 mg/dose) for 1 to 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35118829','lexi-content-ref-33557873','lexi-content-ref-32463092','lexi-content-ref-33211859','lexi-content-ref-32778886','lexi-content-ref-NIH.1','lexi-content-ref-34133855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35118829','lexi-content-ref-33557873','lexi-content-ref-32463092','lexi-content-ref-33211859','lexi-content-ref-32778886','lexi-content-ref-NIH.1','lexi-content-ref-34133855'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a983b958-5c46-43fd-af6b-c8dbe93b1bf2">Nephrotic syndrome, steroid resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrotic syndrome, steroid resistant: </b>Limited data available, variable regimens reported: Children and Adolescents: Pulse therapy: IV (succinate): 15 to 30 mg/kg/dose <b>or </b>500 mg/<b>m<sup>2</sup></b>/dose once daily for 3 days; maximum dose: 1,000 mg/dose. Transition to oral corticosteroid and taper as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32382828','lexi-content-ref-34556256','lexi-content-ref-20108003','lexi-content-ref-27806747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32382828','lexi-content-ref-34556256','lexi-content-ref-20108003','lexi-content-ref-27806747'])">Ref</a></span>). Additional pulse doses may be required; some regimens include multiple pulses over a few months until remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17514629','lexi-content-ref-15523124','lexi-content-ref-15322892','lexi-content-ref-17876609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17514629','lexi-content-ref-15523124','lexi-content-ref-15322892','lexi-content-ref-17876609'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="def5d415-75d0-49eb-a6b1-981e1a2bfe5f">Pneumocystis pneumonia, adjunctive therapy for moderate or severe infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Pneumocystis</b></i>
<b> pneumonia (PCP), </b>
<b>adjunctive therapy for moderate or severe infection:</b> Limited data available: <b>Note:</b> Recommended when on room air PaO<sub>2</sub> &lt;70 mm Hg or PAO<sub>2</sub>-PaO<sub>2</sub> ≥35 mm Hg. Begin as soon as possible after diagnosis and within 72 hours of PCP therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: IV (succinate): 1 mg/kg/dose every 6 hours on days 1 to 7, then 1 mg/kg/dose twice daily on days 8 to 9, then 0.5 mg/kg/dose twice daily on days 10 and 11, and 1 mg/kg/dose once daily on days 12 to 16 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IV (succinate): 30 mg twice daily on days 1 to 5, then 30 mg once daily on days 6 to 10, then 15 mg once daily on days 11 to 21 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce34c998-616f-4720-b6eb-b4024d03070b">Radiocontrast media reaction, prevention of rebound reaction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radiocontrast media reaction, prevention of rebound reaction: </b>Limited data available: <b>Note: </b>If patient is experiencing anaphylaxis, administer epinephrine first. Corticosteroids may be utilized to prevent rebound reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV (succinate): 1 mg/kg/dose; maximum dose: 40 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c7f366c-083b-4b00-891a-1fc19833dbf8">Ulcerative colitis, acute, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, acute, severe: </b> Limited data available: Children and Adolescents: IV (succinate): 1 to 1.5 mg/kg/<b>day</b> once daily or in divided doses 2 times daily; maximum daily dose: 60 mg/<b>day</b>. Higher doses should be reserved for patients with severe disease and/or who have failed oral steroids. Transition to oral therapy when clinically appropriate. If inadequate response after 3 to 5 days of IV therapy, initiate second-line therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51129963"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. The pharmacokinetic and pharmacodynamic properties of methylprednisolone in kidney impairment are not well understood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15634032','lexi-content-ref-25471548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15634032','lexi-content-ref-25471548'])">Ref</a></span>). Methylprednisolone clearance appears unaltered in patients with uremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15634032','lexi-content-ref-11835067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15634032','lexi-content-ref-11835067'])">Ref</a></span>) and it is slightly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15634032','lexi-content-ref-854143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15634032','lexi-content-ref-854143'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51129964"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F195386"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9639" href="/d/html/9639.html" rel="external">see "Methylprednisolone: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Only the methylprednisolone <b>succinate</b> formulation (Solu-Medrol) may be given IV. Methylprednisolone <b>acetate</b> suspension (Depo-Medrol) is intended for IM or intra-articular administration only; do <b>not</b> administer the acetate preparation IV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Grissinger.1','lexi-content-ref-ISMP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Grissinger.1','lexi-content-ref-ISMP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Individualize glucocorticoid dosing and use the minimum effective dose/duration. Evidence to support an optimal dose and duration is lacking for most indications; recommendations provided are general guidelines only.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> HPA-axis suppression is likely in any adult receiving &gt;20 mg/day (daytime dosing) or ≥5 mg per 24 hours (evening or night dosing) for &gt;2 weeks or with Cushingoid appearance (although HPA suppression may occur with lower doses or briefer exposure in some patients); do not abruptly discontinue treatment; dose tapering may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12594318','lexi-content-ref-Furst.2','lexi-content-ref-27105755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12594318','lexi-content-ref-Furst.2','lexi-content-ref-27105755'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV</b>
<b>(succinate):</b> 40 to 125 mg/day given in a single daily dose or in divided doses; rarely, for certain conditions, may go up to 1 to 2 mg/<b>kg</b>/day.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial high-dose “pulse” therapy for select indications (eg, severe systemic rheumatic disorders): 7 to 15 mg/kg/dose (or 500 mg to 1 g/dose) given once daily for 3 to 5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 16 to 64 mg/day once daily or in divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">The following dose taper example is from the commercially available tapered-dosage product:</p>
<p style="text-indent:-2em;margin-left:8em;">Day 1: 24 mg on day 1 administered as 8 mg before breakfast, 4 mg after lunch, 4 mg after supper, and 8 mg at bedtime <b>or</b> 24 mg as a single dose or divided into 2 or 3 doses upon initiation (regardless of time of day).</p>
<p style="text-indent:-2em;margin-left:8em;">Day 2: 20 mg on day 2 administered as 4 mg before breakfast, 4 mg after lunch, 4 mg after supper, and 8 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 3: 16 mg on day 3 administered as 4 mg before breakfast, 4 mg after lunch, 4 mg after supper, and 4 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 4: 12 mg on day 4 administered as 4 mg before breakfast, 4 mg after lunch, and 4 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 5: 8 mg on day 5 administered as 4 mg before breakfast and 4 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 6: 4 mg on day 6 administered as 4 mg before breakfast.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM</b>
<b>(acetate or succinate):</b> 40 to 60 mg as a single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intra-articular (acetate suspension): Note:</b> Dose ranges per manufacturer's labeling. Specific dose is determined based upon joint size, severity of inflammation, amount of articular fluid present, and clinician judgment.</p>
<p style="text-indent:-2em;margin-left:6em;">Larger joint (eg, knee, shoulder, hip): 20 to 80 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Medium joint (eg, wrist, ankle, elbow): 10 to 40 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Small joint (eg, toe, finger): 4 to 10 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intralesional (acetate) (alternative agent):</b>
<b>Note:</b> Other agents (eg, triamcinolone acetonide) may be more commonly employed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mathes.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mathes.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Usual dosage range: 20 to 60 mg; for large lesions, it may be necessary to distribute doses ranging from 20 to 40 mg by repeated local injections; 1 to 4 injections are usually employed with intervals between injections varying with the type of lesion being treated and clinical response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54822daa-4bb4-4bf6-8619-0111182f0825">Acute respiratory distress syndrome, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute respiratory distress syndrome, moderate to severe (off-label use):</b>
<b>Note:</b> May consider in most patients with persistent or refractory, moderate to severe acute respiratory distress syndrome, who are relatively early in the disease course (within 14 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28938253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28938253'])">Ref</a></span>). Use ideal body weight to calculate dose. If patient is extubated between days 1 to 14, advance to day 15 of therapy and taper according to the following schedule. Do not abruptly discontinue since this may cause deterioration due to inflammatory response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17426195','lexi-content-ref-28938253','lexi-content-ref-16625008']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17426195','lexi-content-ref-28938253','lexi-content-ref-16625008'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Example regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28938253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28938253'])">Ref</a></span>):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b>
<b>(succinate):</b> Loading dose of 1 mg/kg over 30 minutes, followed by a gradual taper:</p>
<p style="text-indent:-2em;margin-left:8em;">Days 1 to 14: 1 mg/kg/day in divided doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Days 15 to 21: 0.5 mg/kg/day in divided doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Days 22 to 25: 0.25 mg/kg/day in divided doses.</p>
<p style="text-indent:-2em;margin-left:8em;">Days 26 to 28: 0.125 mg/kg/day in divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c11414eb-e4a9-4f52-b5ec-67ffd22dabf5">Allergic conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic conditions:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Anaphylaxis (adjunct to epinephrine for prevention of late-phase/biphasic reaction):</b></i>
<b> Note:</b> Do <b>not</b> use for initial or sole treatment of anaphylaxis because corticosteroids do not result in the prompt relief of upper or lower airway obstruction or shock (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26505932','lexi-content-ref-24909803','lexi-content-ref-23268454','lexi-content-ref-26525001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26505932','lexi-content-ref-24909803','lexi-content-ref-23268454','lexi-content-ref-26525001'])">Ref</a></span>). Some experts limit use to patients with severe or persistent steroid-responsive symptoms (eg, bronchospasm in patients with asthma) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Campbell.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Campbell.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV (succinate):</b> 1 to 2 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25466802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25466802'])">Ref</a></span>) <b>or</b> 40 to 125 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Campbell.1','lexi-content-ref-Castells.1','lexi-content-ref-23268454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Campbell.1','lexi-content-ref-Castells.1','lexi-content-ref-23268454'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Angioedema (acute allergic) and/or new-onset urticaria:</i> Note:</b> For moderate to severe symptoms without signs of anaphylaxis. Use epinephrine if anaphylaxis symptoms (eg, risk of airway or cardiovascular compromise) are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-Zuraw.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-Zuraw.1'])">Ref</a></span>). In patients with new-onset urticaria, reserve use for those with significant angioedema or with symptoms that are unresponsive to antihistamines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-Asero.1','lexi-content-ref-34536239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-Asero.1','lexi-content-ref-34536239'])">Ref</a></span>). The optimal dosing strategy has not been defined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-34536239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-34536239'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b>
<b>(succinate):</b> Initial: 60 to 80 mg; switch to an oral corticosteroid as soon as possible, tapering the dose for a total treatment duration of ≤10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34536239','lexi-content-ref-Zuraw.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34536239','lexi-content-ref-Zuraw.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: Note:</b> Dose is based on prednisone equivalency. An example regimen is 16 to 48 mg daily initially, followed by a taper over 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Asero.1','lexi-content-ref-34536239','lexi-content-ref-Zuraw.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Asero.1','lexi-content-ref-34536239','lexi-content-ref-Zuraw.1'])">Ref</a></span>). The total treatment duration should not exceed 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34536239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34536239'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85b2fb27-1a4a-40d6-b8b5-ab95601995d8">Asthma, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, acute exacerbation:</b>
<b>Note:</b> For moderate to severe exacerbations or in patients who do not respond promptly and completely to short-acting beta agonists; administer within 1 hour of presentation to emergency department (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral</b>
<b>, IV (succinate):</b> 40 to 60 mg/day in 1 or 2 divided doses for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2','lexi-content-ref-NAEPP.1'])">Ref</a></span>); doses up to 60 to 80 mg every 6 to 12 hours have been used in critically ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.1'])">Ref</a></span>). If symptoms do not resolve and peak expiratory flow is not at least 70% of personal best, then longer treatment may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation (off-label use): Note:</b> In patients with severe but not life-threatening exacerbations, oral regimens are recommended. Use IV route in patients who cannot tolerate oral therapy (eg, shock, mechanically ventilated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1','lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1','lexi-content-ref-Stoller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral;</b>
<b>IV</b>
<b>(succinate):</b> 40 to 60 mg daily for 5 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1','lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1','lexi-content-ref-Stoller.1'])">Ref</a></span>). Doses up to 60 mg every 6 hours have been used in critically ill patients, although outcome data are limited. <b>Note:</b> Dose is based on an equivalent dose of prednisone; optimal dose has not been established. If patient improves with therapy, may discontinue without taper. If patient does not improve, a longer duration of therapy may be indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stoller.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="894e2a7e-3fff-4cb6-8ddb-f11aa30fb548">COVID-19, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, hospitalized patients (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Methylprednisolone is recommended for treatment of COVID-19 in hospitalized patients requiring supplemental oxygen or ventilatory support when dexamethasone is not available or there are specific indications for methylprednisolone. Dosing is extrapolated from a study that used dexamethasone; the equivalent dose of methylprednisolone (or other glucocorticoid) may be substituted if necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-IDSA.2020','lexi-content-ref-NIH.2020','lexi-content-ref-WHO.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-IDSA.2020','lexi-content-ref-NIH.2020','lexi-content-ref-WHO.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral;</b>
<b>IV</b>
<b>(succinate):</b> 32 mg once daily or 16 mg twice daily for up to 10 days (or until discharge, if sooner) as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-IDSA.2020','lexi-content-ref-NIH.2020','lexi-content-ref-WHO.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-IDSA.2020','lexi-content-ref-NIH.2020','lexi-content-ref-WHO.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="38c570b6-3f4a-4617-9a13-c20cd0850cd7">Deceased organ donor management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Deceased organ donor management (hormonal resuscitation for the deceased organ donor) (off-label use): Note:</b> Data supporting benefit are conflicting; if given, it should be administered after blood has been collected for tissue typing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24980425','lexi-content-ref-25978154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24980425','lexi-content-ref-25978154'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV</b>
<b>(succinate):</b> Regimens include: 1 g (as an IV infusion) <b>or</b> 15 mg/kg (as an IV infusion) <b>or</b> 250 mg (as an IV bolus) followed by a continuous infusion at 100 mg/hour; usually given as part of combination hormone therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25978154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25978154'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd1bdfb0-f04d-4bd1-896f-dcb090cb438a">Giant cell arteritis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Giant cell arteritis, treatment: Note:</b> Due to the rapidly progressive nature of the disease, start treatment <b>immediately</b> once diagnosis is highly suspected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20371504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20371504'])">Ref</a></span>). In patients presenting <b>without</b> threatened/evolving vision loss, an oral glucocorticoid is suggested as initial therapy rather than IV methylprednisolone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Salvarani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Salvarani.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial pulse therapy in patients presenting <b>with</b> threatened/evolving vision loss:</i>
<b>IV (succinate):</b> 500 mg to 1 g daily for 3 days, followed by an oral glucocorticoid (eg, prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20371504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20371504'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a81184b-235e-4be1-8cc9-23a33b10cc65">Gout, treatment, acute flares</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, treatment, acute flares:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid use in patients with known or suspected septic arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intra-articular (acetate): Note: </b>Consider in patients with gout flare limited to 1 or 2 affected joints; clinicians must have sufficient expertise to perform arthrocentesis and injection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32391934','lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32391934','lexi-content-ref-Gaffo.1'])">Ref</a></span>). May mix with an equal volume of local anesthetic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12152964','lexi-content-ref-Roberts.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12152964','lexi-content-ref-Roberts.1'])">Ref</a></span>). Dose is individualized based on joint size, disease severity, and clinician judgment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.1'])">Ref</a></span>). Typical doses are:</p>
<p style="text-indent:-2em;margin-left:6em;">Large joint (eg, knee): 40 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Medium joint (eg, wrist, ankle, elbow): 30 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Small joint (eg, toe, finger): 10 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: Note:</b> Dose is based on an equivalent dose of prednisone.</p>
<p style="text-indent:-2em;margin-left:6em;">24 to 32 mg/day given once daily or in 2 divided doses until symptom improvement (usually 2 to 5 days), then taper gradually as tolerated (typically over 7 to 10 days); a slower taper (eg, over 14 to 21 days) may be required, particularly in patients with multiple recent flares (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27802508','lexi-content-ref-23024029','lexi-content-ref-27457514','lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27802508','lexi-content-ref-23024029','lexi-content-ref-27457514','lexi-content-ref-Gaffo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM (acetate or succinate) (alternative route): Note:</b> Reserve for patients who are not candidates for oral therapies or intra-articular glucocorticoid administration.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 40 to 60 mg as a single dose; may repeat at ≥48-hour intervals if benefit fades or there is no flare resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (succinate) (alternative route): Note:</b> Reserve for patients who are not candidates for oral therapies or intra-articular glucocorticoid administration.</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: 20 mg twice daily until clinical improvement (usually 2 to 5 days), then taper gradually as tolerated (typically over 7 to 10 days); transition to an equivalent dose of an oral glucocorticoid (eg, prednisone) as soon as possible to complete taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23024029','lexi-content-ref-Gaffo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23024029','lexi-content-ref-Gaffo.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ba4cbc5f-890b-41ec-b2b1-c3687f7e3787">Graft-versus-host disease, acute, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-vs-host disease, acute, treatment (off-label use): Note:</b> For grade ≥2 acute graft-versus-host disease. An optimal regimen has not been identified; refer to institutional protocols as variations exist. Treatment is dependent on the severity and the rate of progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22510384','lexi-content-ref-23892326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22510384','lexi-content-ref-23892326'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV</b>
<b>(succinate):</b> Initial: 2 mg/kg/day in 2 divided doses; dose may vary based on organ involvement and severity. Continue for several weeks, then taper over several months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22510384','lexi-content-ref-23892326','lexi-content-ref-Zeiser.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22510384','lexi-content-ref-23892326','lexi-content-ref-Zeiser.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0e8695a-ab23-4579-8a2a-e35dd8656c8d">IgA nephropathy, primary, nonvariant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>IgA nephropathy, primary, nonvariant (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> May consider for use in selected patients at high risk of chronic kidney disease progression (eg, proteinuria ≥0.75 to 1 g/day) despite 3 to 6 months of optimized doses of nonimmunosuppressive therapies (eg, renin-angiotensin system inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.1','lexi-content-ref-34556256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.1','lexi-content-ref-34556256'])">Ref</a></span>). The optimal dose of methylprednisolone has not been established and may vary based on institutional protocols and patient-specific factors; an example regimen is provided below.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 0.4 mg/kg once daily for 2 months (maximum dose: 32 mg/day). Taper daily dose every month over an additional 4 to 7 months. <b>Note: </b>Antimicrobial prophylaxis for <i>Pneumocystis</i> pneumonia was also prescribed for the first 12 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35579642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35579642'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="933c83ae-dd8f-4366-94d5-7f5cfe4d6c9e">Immune-mediated adverse reactions associated with checkpoint inhibitor therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune-mediated adverse reactions associated with checkpoint inhibitor therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider withholding checkpoint inhibitor therapy for most grade 2 toxicities, withholding the checkpoint inhibitor for grade 3 toxicity, and permanently discontinuing for most grade 4 toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). Refer to each checkpoint inhibitor monograph for specific dosage modification and management details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cardiovascular toxicity: Myocarditis, pericarditis, arrhythmias, impaired ventricular function with heart failure, or vasculitis; for patients without an immediate response to high-dose corticosteroids (eg, prednisone): </i>
<b>IV: </b>1 g once daily in combination with other immunosuppressive therapy; once clinically stable, taper methylprednisolone over a minimum of 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392','lexi-content-ref-30715219']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392','lexi-content-ref-30715219'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dermatologic toxicity:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bullous dermatoses, grade 3 or 4:</i>
<b> IV: </b>1 to 2 mg/kg/day; convert to oral corticosteroids when appropriate; taper over at least 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Rash or inflammatory dermatitis, grade 4:</i>
<b> IV: </b>1 to 2 mg/kg/day with slow tapering once toxicity resolves (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe cutaneous adverse reaction, grade 3: </i>
<b>IV: </b>0.5 to 1 mg/kg/day; convert to oral corticosteroids on response; taper over 4 at least weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe cutaneous adverse reaction, grade 4: </i>
<b>IV: </b>1 to 2 mg/kg/day with tapering when toxicity resolves to normal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GI toxicity: Colitis, grade 4 (may also consider for grade 3, particularly with concurrent upper GI inflammation): </i>
<b>IV: </b>1 to 2 mg/kg/day until symptoms improve to grade 1 and then taper over 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematologic conditions: Acquired thrombotic thrombocytopenic purpura, grade 3 or 4: </i>
<b>IV: </b>1 g once daily for 3 days; begin the first dose immediately after plasma exchange. If no exacerbation within 3 to 5 days after stopping plasma exchange, taper corticosteroids over 2 to 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hepatotoxicity: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hepatitis, grade 3: </i>
<b>IV: </b>1 to 2 mg/kg/day; attempt taper around 4 to 6 weeks when symptoms improve to ≤ grade 1; re-escalate if needed. If steroid refractory, consider liver biopsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hepatitis, grade 4: </i>
<b>IV: </b>2 mg/kg/day; attempt taper around 4 to 6 weeks when symptoms improve to ≤ grade 1; re-escalate if needed. If steroid refractory, consider liver biopsy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Note: </b></i>Based on data from a retrospective cohort study in patients with grade 3 or 4 immune-mediated hepatitis, initial treatment with methylprednisolone 1 mg/kg/day demonstrated similar time to ALT normalization (compared with higher methylprednisolone doses), while reducing the potential for corticosteroid-related complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34709662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34709662'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Musculoskeletal toxicities: Myositis, grade 3 or 4 with severe compromise: </i>
<b>IV: </b>1 to 2 mg/kg/day or higher dose bolus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nervous system toxicities:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Aseptic meningitis, moderate to severe symptoms:</i>
<b> IV: </b>1 mg/kg/day, taper after 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Autonomic neuropathy, grade 3 or 4: </i>
<b>IV: </b>1 g once daily for 3 days, followed by oral corticosteroid taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Demyelinating diseases, grade 3 or 4: </i>
<b>IV: </b>1 g once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Encephalitis: </i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Any grade: </i>
<b>IV: </b>1 to 2 mg/kg/day; taper over at least 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Severe or progressing symptoms or the presence of oligoclonal bands: </i>
<b>IV: </b>1 g once daily for 3 to 5 days (in combination with IVIG or plasmapheresis); taper over at least 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Guillain-Barré syndrome: </i>
<b>Note:</b> Corticosteroids are usually not recommended for idiopathic Guillain-Barré syndrome (GBS); however, a trial of methylprednisolone may be reasonable with checkpoint inhibitor immune-mediated GBS (refer to guideline for details). <b>IV:</b> 2 to 4 mg/kg/day followed by a slow taper; for grade 3 or 4 GBS, may consider pulse dosing of 1 g once daily for 5 days (with taper over 4 to 6 weeks) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Peripheral neuropathy, grade 3 or 4:</i> Initial dose:<b> IV:</b> 2 to 4 mg/kg/day followed by a slow taper; refer to guideline for further details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ocular toxicity: Uveitis or iritis, grade 4: </i>
<b>IV: </b>0.8 to 1.6 mg/kg/day in combination with intravitreal or periocular or topical ophthalmic corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary toxicity: Pneumonitis grade 3 or 4: </i>
<b>IV: </b>1 to 2 mg/kg/day with taper over 4 to 6 weeks (or longer for chronic pneumonitis); if not improved within 48 hours, may add additional immunosuppressant agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Corticosteroid conversion and tapering (general recommendations):</i> When converting from IV corticosteroids to oral, the initial conversion from methylprednisolone ≥1 mg/kg IV is to oral prednisone 1 mg/kg/day at minimum (refer to Prednisone monograph for prednisone tapering). Steroid tapering should occur slowly, generally over 4 weeks or longer, with the length of the taper correlating with the severity of the immune-mediated adverse event, the initial corticosteroid dose, and individual patient response. For immune-mediated hepatitis, steroid taper may be attempted at ~4 to 6 weeks (when ≤ grade 1); re-escalate, if needed. Monitor closely for rebound or recurrence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58acdf8a-6a05-45e7-a020-bd4c6e72f2ed">Immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia (initial therapy): Note:</b> Goal of therapy is to provide a safe platelet count to prevent clinically important bleeding rather than normalization of the platelet count (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Patients with severe bleeding (in combination with other treatments):</b></i>
<b>IV</b>
<b>(succinate):</b> 1 g once daily for 3 doses and then stop (no taper) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.1','lexi-content-ref-2449258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.1','lexi-content-ref-2449258'])">Ref</a></span>). <b>Note:</b> Due to the short-term response, maintenance therapy with an oral glucocorticoid (eg, prednisone) may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31770441'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9117d6e1-33df-4646-bf4f-7e3751815245">Inflammatory bowel disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inflammatory bowel disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Crohn disease, acute (eg, severe/fulminant disease and/or unable to take oral) (adjunctive agent):</i> Note: Not</b> for long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508'])">Ref</a></span>). In patients with localized peritonitis, some experts recommend against initiating corticosteroids due to the potential of masking further clinical deterioration; however, if already receiving corticosteroids, continued use may be appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hashash.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b>
<b>(succinate):</b> 40 to 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> For patients who have been receiving chronic treatment with a corticosteroid, a small increase in their daily dose may be required during an acute exacerbation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hashash.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hashash.1'])">Ref</a></span>). Steroid-sparing agents (eg, biologic agents, immunomodulators) should be introduced with a goal of discontinuing corticosteroid therapy as soon as possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Ulcerative colitis, acute (severe or fulminant): </i>Note: Not</b> for long-term use.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b>
<b>(succinate):</b> 40 to 60 mg/day in 1 to 3 divided doses. If response to treatment is inadequate after 5 days (severe) or 3 days (fulminant), second-line therapy is initiated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605','lexi-content-ref-31945371','lexi-content-ref-Peppercorn.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605','lexi-content-ref-31945371','lexi-content-ref-Peppercorn.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56b6caea-ebbf-4c1e-93f2-543c99fc4e9b">Iodinated contrast media allergic-like reaction, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iodinated contrast media allergic-like reaction, prevention: Note:</b> Generally reserved for patients with a prior allergic-like or unknown-type iodinated contrast reaction who will be receiving another iodinated contrast agent. Nonurgent premedication with an oral corticosteroid is generally preferred when contrast administration is scheduled to begin in ≥12 hours; however, consider an urgent (accelerated) regimen with an IV corticosteroid for those requiring contrast in &lt;12 hours. Efficacy of premedication regimens starting &lt;4 to 5 hours before the use of contrast has not been demonstrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Nonurgent regimen:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 32 mg administered 12 hours and 2 hours before contrast medium administration in combination with oral or IV diphenhydramine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1','lexi-content-ref-Davenport.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1','lexi-content-ref-Davenport.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Urgent (accelerated) regimen:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV</b>
<b>(succinate):</b> 40 mg every 4 hours until contrast medium administration in combination with IV diphenhydramine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>). Some experts administer methylprednisolone 40 mg at 5 hours and 1 hour before contrast medium administration in combination with diphenhydramine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davenport.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davenport.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e6dff87-980d-4d42-adcd-93ba292bb21e">Multiple sclerosis, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, acute exacerbation: Note:</b> For patients with an acute exacerbation resulting in neurologic symptoms and increased disability or impairments in vision, strength, or cerebellar function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Olek.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Olek.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial pulse therapy:</i>
<b>IV</b>
<b>(succinate):</b> 500 mg to 1 g daily for 3 to 7 days (5 days typically), either alone or followed by an oral taper with prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24507531','lexi-content-ref-26135706','lexi-content-ref-19566504','lexi-content-ref-NICE.1','lexi-content-ref-Olek.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24507531','lexi-content-ref-26135706','lexi-content-ref-19566504','lexi-content-ref-NICE.1','lexi-content-ref-Olek.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c1492fd-1240-46a0-a8e1-affa8298a29c">Myopathies, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myopathies (dermatomyositis/polymyositis), treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial pulse therapy in patients presenting <b>with</b> severe systemic involvement or profound weakness:</i>
<b>IV</b>
<b>(succinate):</b> 1 g daily for 3 to 5 days, followed by oral prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365201','lexi-content-ref-25641317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365201','lexi-content-ref-25641317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="23611861-7f6a-4142-b6d9-dbfa9fc607e3">Nausea and vomiting of pregnancy, severe/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nausea and vomiting of pregnancy, severe/refractory (off-label use): Note:</b> Reserve use as an add-on therapy when all other pharmacologic regimens have failed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (succinate):</b> 16 mg every 8 hours for 3 days. If no response within 3 days, discontinue treatment. If symptoms improve, complete 3-day course of treatment, then taper dose over 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29266076','lexi-content-ref-9790371']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29266076','lexi-content-ref-9790371'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a91e469d-5047-4382-8fc7-9e8aba1103ca">
<i>Pneumocystis </i>pneumonia, adjunctive therapy for moderate to severe disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis</i> pneumonia, adjunctive therapy for moderate to severe disease (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended for patients with PaO<sub>2</sub> &lt;70 mm Hg on room air or PAO<sub>2</sub>-PaO<sub>2</sub> ≥35 mm Hg on room air (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>); some experts additionally recommend for patients with oxygen saturation &lt;92% on room air (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sax.1','lexi-content-ref-Thomas.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sax.1','lexi-content-ref-Thomas.2019'])">Ref</a></span>). Dosing is based on an equivalent dose of prednisone.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (succinate):</b> 30 mg twice daily on days 1 to 5 beginning as early as possible, followed by 30 mg once daily on days 6 to 10, then 15 mg once daily on days 11 to 21 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23465020','lexi-content-ref-HHS.1','lexi-content-ref-Sax.1','lexi-content-ref-Thomas.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23465020','lexi-content-ref-HHS.1','lexi-content-ref-Sax.1','lexi-content-ref-Thomas.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a0d01f-7598-4295-91fc-098cdd1ce6dd">Prostate cancer, metastatic, castration resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration-resistant (off-label use):</b>
<b>Oral:</b> 4 mg twice daily (in combination with <i>
<b>micronized </b></i>abiraterone acetate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29150328']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29150328'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="521d727e-2a1c-4792-a4e8-667090d41297">Sarcoidosis, severe, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sarcoidosis, severe, acute (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with life-threatening extrapulmonary disease manifestations (eg, ventricular arrhythmias, transverse myelitis) or rapidly progressive disease (eg, severe optic neuritis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34607912','lexi-content-ref-33268456','lexi-content-ref-33611981','lexi-content-ref-34143362','lexi-content-ref-34524933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34607912','lexi-content-ref-33268456','lexi-content-ref-33611981','lexi-content-ref-34143362','lexi-content-ref-34524933'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Fixed dose: </i></b>
<b>IV (succinate): </b>500 mg/day to 1 g per day for 3 to 5 days, followed by an oral glucocorticoid (eg, prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34607912','lexi-content-ref-15525844','lexi-content-ref-27007482','lexi-content-ref-33611981','lexi-content-ref-34143362','lexi-content-ref-34524933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34607912','lexi-content-ref-15525844','lexi-content-ref-27007482','lexi-content-ref-33611981','lexi-content-ref-34143362','lexi-content-ref-34524933'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Weight-based dosing</i>
<i>: </i>IV (succinate): </b>10 to 20 mg/kg/day for 3 days, followed by an oral glucocorticoid (eg, prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15525844','lexi-content-ref-15167067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15525844','lexi-content-ref-15167067'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e06fe95b-34c0-41e4-9354-aeafaf1c1234">Systemic rheumatic disorders, organ-threatening or life-threatening</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic rheumatic disorders (eg, antineutrophil cytoplasmic antibody-associated vasculitis, mixed cryoglobulinemia syndrome, polyarteritis nodosa, rheumatoid arthritis, systemic lupus erythematosus), organ-threatening or life-threatening: Note:</b> The following dosage ranges are for guidance only; dosing should be highly individualized, taking into account disease severity, the specific disorder, and disease manifestations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial pulse therapy (optional):</i>
<b>IV</b>
<b>(succinate):</b> 7 to 15 mg/kg/day (maximum dose: 500 mg to 1 g/day) typically for up to 3 days, followed by an oral glucocorticoid (eg, prednisone); may be given as part of an appropriate combination regimen. Lower doses (eg, 250 mg/day) may be appropriate in some patients (eg, less severe manifestations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fervenza.1','lexi-content-ref-25399938','lexi-content-ref-Merkel.1','lexi-content-ref-27799164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fervenza.1','lexi-content-ref-25399938','lexi-content-ref-Merkel.1','lexi-content-ref-27799164'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27c26744-c3f9-4483-b251-c64b4a51b7e5">Thyroid eye disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid eye disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In patients with sight-threatening disease (eg, compressive optic neuropathy), urgent administration of IV glucocorticoids is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36480280','lexi-content-ref-34297684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36480280','lexi-content-ref-34297684'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sight-threatening disease:</i>
<b>IV (succinate):</b> 500 mg to 1 g daily or every other day for 3 doses during the first week with daily monitoring of response. In patients without disease response after ~7 days, orbital decompression surgery is required. In patients with disease response, may repeat this dosing cycle during the second week, followed by lower doses of IV or oral glucocorticoids thereafter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36480280','lexi-content-ref-24417307','lexi-content-ref-34297684','lexi-content-ref-16117821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36480280','lexi-content-ref-24417307','lexi-content-ref-34297684','lexi-content-ref-16117821'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Moderate to severe disease:</i>
<b>IV</b>
<b>(succinate):</b> 500 mg once weekly for 6 weeks, followed by 250 mg once weekly for an additional 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36480280','lexi-content-ref-34297684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36480280','lexi-content-ref-34297684'])">Ref</a></span>). <b>Note: </b>If response is inadequate after 6 to 8 weeks or if disease progresses, consider alternative treatment options or administering an additional course of methylprednisolone (limit cumulative dose to ≤8 g) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36480280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36480280'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="992a0682-8a0f-4293-8ad0-146fa7ebf6a0">Warm autoimmune hemolytic anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Warm autoimmune hemolytic anemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV</b>
<b>(succinate):</b> 250 mg to 1 g daily for 1 to 3 days, followed by an oral glucocorticoid (eg, prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20656187','lexi-content-ref-25271314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20656187','lexi-content-ref-25271314'])">Ref</a></span>); a clinician experienced with the treatment of hemolytic anemia should be involved with therapy.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991602"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The pharmacokinetics and pharmacodynamics of methylprednisolone in kidney impairment are not well understood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15634032','lexi-content-ref-25471548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15634032','lexi-content-ref-25471548'])">Ref</a></span>). Methylprednisolone clearance appears unaltered in patients with uremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15634032','lexi-content-ref-11835067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15634032','lexi-content-ref-11835067'])">Ref</a></span>) and it is slightly dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15634032','lexi-content-ref-854143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15634032','lexi-content-ref-854143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b> No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988821"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F57428759"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Adrenal suppression (tertiary adrenal insufficiency)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal suppression</b> (tertiary adrenal insufficiency) may occur with glucocorticoids, including methylprednisolone, and results from inadequate stimulation of the adrenal glands (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Akahosi.1','lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Akahosi.1','lexi-content-ref-31223468'])">Ref</a></span>). Glucocorticoid-induced adrenal insufficiency usually resolves with discontinuation of methylprednisolone, but symptoms may persist for 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34253540','lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34253540','lexi-content-ref-29184808'])">Ref</a></span>). Adrenal insufficiency may lead to adrenal crisis, a life-threatening emergency that may present like a hypotensive shock state (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>). High-dose methylprednisolone therapy for conditions such as Crohn disease in females who are pregnant may cause adrenal suppression in the newborn (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18784429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18784429'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; occurs due to lack of or diminished cortisol production by the adrenal gland (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468','lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468','lexi-content-ref-29184808'])">Ref</a></span>). Exogenous glucocorticoids produce a similar negative feedback mechanism as endogenous cortisol, causing a subsequent decrease in adrenocorticotrophic hormone (ACTH) secretion; thus, cortisol production is suppressed, resulting in adrenal atrophy and subsequent insufficiency (ie, hypothalamic-pituitary-adrenal-axis [HPA-axis] suppression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468','lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468','lexi-content-ref-29184808'])">Ref</a></span>). In times of stress (eg, critical illness, trauma, surgery), the body requires stress doses in patients taking glucocorticoids chronically (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; acute (minutes after administration) and/or chronic (2 to 20 hours to days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184808'])">Ref</a></span>). Chronic glucocorticoid use does not allow for the HPA axis to recover quickly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High doses for prolonged periods: Although some patients may become HPA suppressed with lower doses or briefer exposure, some experts consider HPA-axis suppression likely in any adult receiving a dose comparable to prednisone &gt;20 mg/day (daytime dosing) or a dose comparable to prednisone ≥5 mg per 24 hours (evening or night dosing) for &gt;3 weeks or with cushingoid appearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27105755','lexi-content-ref-33923971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27105755','lexi-content-ref-33923971'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Nighttime administration may inhibit early morning ACTH surge (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Akahosi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Akahosi.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Potency of glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent interacting medications (eg, carbamazepine, St John's wort, mitotane, rifampicin, itraconazole, diltiazem, thyroid replacement therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of previous adrenal crisis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of glucocorticoid therapy delivered by various routes of administration (oral and inhaled greater risk than topical or intra-articular) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Akahosi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Akahosi.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone growth inhibition</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids may inhibit bone growth (linear growth) in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21234507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21234507'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose-related; glucocorticoids decrease bone formation and increase bone resorption by a combination of factors, including decreasing calcium absorption and increasing calcium secretion; suppressing the somatotropic axis, resulting in suppressed growth hormone secretion; and increasing catabolism of the bone protein matrix and decreasing sex hormone production (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21234507','lexi-content-ref-32036458','lexi-content-ref-23381030','lexi-content-ref-3068012','lexi-content-ref-34655742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21234507','lexi-content-ref-32036458','lexi-content-ref-23381030','lexi-content-ref-3068012','lexi-content-ref-34655742'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32036458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32036458'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS and psychiatric/behavioral effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including methylprednisolone, may cause a myriad of CNS and psychiatric/behavioral adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696'])">Ref</a></span>). Patients may develop <b>apathy</b> or <b>depression</b>. More commonly, patients develop excitatory <b>psychiatric disturbances</b> (including agitation, anxiety, distractibility, fear, hypomania, insomnia, irritability, lethargy, labile mood, mania, pressured speech, restlessness, and tearfulness) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696'])">Ref</a></span>). Exact incidences are unclear but range from 1.8% to 57% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17036562'])">Ref</a></span>). Severe psychiatric effects have been reported in 6% of adults receiving high-dose regimens, while depression or mania have been reported in 36% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24943696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24943696'])">Ref</a></span>). Larger doses of methylprednisolone (500 to 1,000 mg) may be associated with more hypomania or mania (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23157995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23157995'])">Ref</a></span>). Discontinuation or dose reductions generally resolve symptoms over days to weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24943696','lexi-content-ref-26034636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24943696','lexi-content-ref-26034636'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; not clearly established. Methylprednisolone and other glucocorticoids may alter feedback on the hypothalamic-pituitary-adrenal axis, which may lead to mood changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31656440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31656440'])">Ref</a></span>). Glucocorticoids may induce glutamate release, which may be responsible for neuronal toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992'])">Ref</a></span>). Exogenous glucocorticoids may also inhibit synthesis of cortical GABAergic steroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23157995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23157995'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most cases occur early in treatment (within the first 5 days), average of 11.5 days. The majority develop within 6 weeks of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-26034636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-26034636'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (comparable to prednisone ≥80 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Possible additional risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;30 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22764363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22764363'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-17036562'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of neuropsychiatric disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22764363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22764363'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cushingoid features/Cushing syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids may cause a<b> cushingoid appearance</b> (truncal obesity, facial adipose tissue, dorsocervical adipose tissue) which are adverse reactions related to patient's physical features (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15850848','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15850848','lexi-content-ref-23947590'])">Ref</a></span>). Reactions are more metabolic than <b>weight gain</b>, which is related to fluid retention (edema) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>). Iatrogenic <b>Cushing syndrome </b>resulting from glucocorticoid therapy increases morbidity and mortality and decreases quality of life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27177728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27177728'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; excess cortisol from exogenous source (methylprednisolone) results in suppression of adrenocorticotrophic hormone, commonly called iatrogenic Cushing syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15850848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15850848'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; may develop within the first 2 months of glucocorticoid therapy, with the risk dependent on the dose and duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18684744','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18684744','lexi-content-ref-23947590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744','lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Drug interactions prolonging the half-life of glucocorticoids via cytochrome P450 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• BMI (high) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Daily caloric intake (&gt;30 kcal/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including methylprednisolone, may cause GI effects, including <b>peptic ulcer</b> (with possible perforation and hemorrhage), dyspepsia, gastritis, <b>abdominal distention</b>, and <b>ulcerative esophagitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>). Meta-analyses suggest that glucocorticoid monotherapy carries little to no risk of peptic ulcer disease in the general population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133','lexi-content-ref-23947590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; glucocorticoids inhibit gastroprotective prostaglandin synthesis and reduce gastric mucus and bicarbonate secretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23919213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23919213'])">Ref</a></span>). Glucocorticoid immunosuppressive effects may prevent wound healing as well as mask GI signs and symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24833682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24833682'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher methylprednisolone doses (≥4 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26096497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26096497'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent aspirin or nonsteroidal anti-inflammatory drugs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21357821','lexi-content-ref-23919213','lexi-content-ref-24833682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21357821','lexi-content-ref-23919213','lexi-content-ref-24833682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hospitalized (but not ambulatory) patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24833682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24833682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent methylprednisolone users (7 to 28 days) versus remote or nonusers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26096497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26096497'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including methylprednisolone, may provoke new-onset <b>hyperglycemia </b>in patients without a history of diabetes and may cause an <b>exacerbation of diabetes mellitus</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23090580','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23090580','lexi-content-ref-26240704'])">Ref</a></span>). Glucose levels have been noted to increase 68% above baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26240704'])">Ref</a></span>). Certain patient populations (eg, transplant, cancer, chronic rheumatologic conditions) are at particular risk due to medication combinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23090580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23090580'])">Ref</a></span>). Resolution may occur within 12 to 16 hours after methylprednisolone discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28836444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28836444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; increased insulin resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23090580','lexi-content-ref-22187441','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23090580','lexi-content-ref-22187441','lexi-content-ref-26240704'])">Ref</a></span>). May also interfere with insulin signaling by direct effects on the insulin receptor and the glucose transporter and may promote gluconeogenesis via liver stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26240704','lexi-content-ref-28836444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26240704','lexi-content-ref-28836444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; 6 hours, with a peak of 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26240704','lexi-content-ref-28836444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26240704','lexi-content-ref-28836444'])">Ref</a></span>). Rapid onset of steroid-induced hyperglycemia occurred within 2 days after initiation of glucocorticoids with a peak in the late afternoon following daily dosing in the morning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23298665','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23298665','lexi-content-ref-26240704'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose and type of glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386','lexi-content-ref-26240704'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386','lexi-content-ref-26240704'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Divided dosing versus once-daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26240704'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV and oral routes of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386','lexi-content-ref-22187441','lexi-content-ref-26240704','lexi-content-ref-28836444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386','lexi-content-ref-22187441','lexi-content-ref-26240704','lexi-content-ref-28836444'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• BMI &gt;25 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386','lexi-content-ref-22187441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386','lexi-content-ref-22187441'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• African American or Hispanic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386','lexi-content-ref-22187441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386','lexi-content-ref-22187441'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• eGFR &lt;40 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• HbA<sub>1c</sub> ≥6% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of gestational diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386','lexi-content-ref-22187441','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386','lexi-content-ref-22187441','lexi-content-ref-26240704'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386','lexi-content-ref-22187441','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386','lexi-content-ref-22187441','lexi-content-ref-26240704'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of mycophenolate mofetil and calcineurin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386','lexi-content-ref-22187441','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386','lexi-content-ref-22187441','lexi-content-ref-26240704'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous history of impaired fasting glucose or impaired glucose tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386','lexi-content-ref-22187441','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386','lexi-content-ref-22187441','lexi-content-ref-26240704'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including methylprednisolone, have immunosuppressive and anti-inflammatory effects that are reversible with discontinuation. <b>Infection</b> may occur after prolonged use, including <i>Pneumocystis jirovecii pneumonia</i> (PJP), herpes zoster, tuberculosis, and other more common bacterial infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26611557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26611557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; related to pharmacologic action (ie, multiple activities on cell macrophage production and differentiation, inhibition of T-cell activation, effects on dendritic cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8239251','lexi-content-ref-26611557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8239251','lexi-content-ref-26611557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; in one study, the median duration of glucocorticoid use prior to PJP diagnosis was 12 weeks but also occurred earlier or later in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8538233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8538233'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher dose and longer duration of glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22241902','lexi-content-ref-23982055','lexi-content-ref-23137579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22241902','lexi-content-ref-23982055','lexi-content-ref-23137579'])">Ref</a></span>); however, may also increase risk at lower doses (eg, prednisone ≤5 mg/day or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32956604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32956604'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22241902','lexi-content-ref-23982055','lexi-content-ref-26611557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22241902','lexi-content-ref-23982055','lexi-content-ref-26611557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised state (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26611557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26611557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications (immunosuppressive) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22241902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22241902'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rheumatoid arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23137579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23137579'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Interstitial lung disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23982055'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22241902','lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22241902','lexi-content-ref-23982055'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23982055'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low performance status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23982055'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuromuscular and skeletal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoid (including methylprednisolone)-induced neuromuscular and skeletal effects can take the form of various pathologies in patients ranging from <b>osteoporosis</b> and <b>vertebral compression fracture</b> to <b>myopathy</b> to <b>osteonecrosis</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472'])">Ref</a></span>). Glucocorticoid use is the most common cause of secondary osteoporosis; may be underrecognized and undertreated due to underestimation of risk in this patient population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17982350','lexi-content-ref-26509049','lexi-content-ref-25905379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17982350','lexi-content-ref-26509049','lexi-content-ref-25905379'])">Ref</a></span>). Vertebral fractures are the most common glucocorticoid-related fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590'])">Ref</a></span>). Myopathies can also occur secondary to direct skeletal muscle catabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>). Acute <b>steroid myopathy</b> is rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462474'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; glucocorticoids have direct/indirect effects on bone remodeling with osteoblast recruitment decreasing and apoptosis increasing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472'])">Ref</a></span>). Myopathies or <b>myasthenia</b> result from reductions in protein synthesis and protein catabolism, which can manifest as proximal muscle weakness and atrophy in the upper and lower extremities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; vertebral fracture risk is increased within 3 months of initiation and peaks at 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-related risks:</p>
<p style="text-indent:-2em;margin-left:8em;">• Cumulative dose of glucocorticoids prednisone &gt;5 g or equivalent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Children receiving ≥4 courses of glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17332238','lexi-content-ref-12733732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17332238','lexi-content-ref-12733732'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Prednisone ≥2.5 to 7.5 mg daily or equivalent for ≥3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Myopathy may occur at prednisone doses ≥10 mg/day or equivalent, with higher doses potentiating more of a rapid onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Fluorinated glucocorticoid preparations (eg, dexamethasone, betamethasone, triamcinolone) have a higher risk of myopathies than methylprednisolone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20471889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20471889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">General fracture risks:</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• BMI &lt;18.5 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bone mineral T score below -1.5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Endocrine disorders (eg, hypogonadism, hyper- or hypoparathyroidism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Excess alcohol use (&gt;2 units/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of falls (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Malabsorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Menopause and duration of menopause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• White race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients with cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20471889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20471889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Previous fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Underlying inflammatory condition in all ages (eg, inflammatory bowel disease, rheumatoid arthritis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507','lexi-content-ref-17332238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507','lexi-content-ref-17332238'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoid (including methylprednisolone)-induced ocular effects may include <b>increased intraocular pressure</b> (IOP), <b>glaucoma </b>(open-angle), and <b>subcapsular posterior</b>
<b>cataract</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15932528','lexi-content-ref-28924342','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15932528','lexi-content-ref-28924342','lexi-content-ref-21757964'])">Ref</a></span>). Cataracts may persist after discontinuation of glucocorticoid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21666852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21666852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; glucocorticoids can induce cataracts by covalently bonding to lens proteins, causing destabilization of the protein structure, and oxidative changes leading to cataracts formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9464184','lexi-content-ref-28924342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9464184','lexi-content-ref-28924342'])">Ref</a></span>). There are various proposed mechanisms of IOP contributing to glaucoma, including accumulation of polymerized glycosaminoglycans in the trabecular meshwork, producing edema and increasing outflow resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28924342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28924342'])">Ref</a></span>). Another mechanism may include inhibition of phagocytic endothelial cells, leading to accumulation of aqueous debris (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28924342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28924342'])">Ref</a></span>). Glucocorticoids can also alter the trabecular meshwork causing an increase in nuclear size and DNA content (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>). In addition, they can decrease the synthesis of prostaglandins which regulate the aqueous outflow (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; cataracts may occur at least 1 year after initiation of chronic glucocorticoid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17900234','lexi-content-ref-3541262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17900234','lexi-content-ref-3541262'])">Ref</a></span>). IOP may occur at 4 years or more after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590','lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Topical &gt; Systemic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of use in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of open-angle glaucoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590','lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type I diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17900234','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17900234','lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High myopia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590','lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pseudophakia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior vitrectomies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Connective tissue disease and sex (eg, rheumatoid arthritis in males) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients or age &lt;6 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Angle recessive glaucoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F195349"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reactions listed may include other corticosteroids and may not be specifically reported for methylprednisolone.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac arrhythmia, cardiomegaly, circulatory shock, edema, embolism (fat), heart failure (in susceptible patients), hypertension, hypertrophic cardiomyopathy (premature infants), myocardial rupture (after recent myocardial infarction), syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis, venous thrombosis (Johannesdottir 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, allergic dermatitis, atrophic striae, burning sensation of skin, diaphoresis, ecchymoses, epidermal thinning, erythema of skin, exfoliation of skin, facial erythema, hyperpigmentation, hypertrichosis, hypopigmentation, inadvertent suppression of skin test reaction, skin atrophy, skin rash, thinning hair (scalp), urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenal suppression (Dineen 2019), calcinosis (intraarticular or intralesional), Cushing syndrome (iatrogenic) (Pivonello 2016), Cushingoid appearance (Liu 2013), decreased serum potassium, exacerbation of diabetes mellitus (Tamez-Pérez 2015), fluid retention, growth retardation (children), hirsutism, hyperglycemia (Tamez-Pérez 2015), hypokalemic alkalosis, impaired glucose tolerance (Tamez-Pérez 2015), menstrual disease, moon face (Liu 2013), negative nitrogen balance (due to protein catabolism), prediabetes, sodium retention, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (Liu 2013), hiccups, impaired intestinal carbohydrate absorption, increased appetite, intestinal perforation, nausea, pancreatitis, peptic ulcer (with possible perforation and hemorrhage) (Liu 2013), ulcerative esophagitis (Liu 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Glycosuria, spermatozoa disorder (including asthenospermia and oligospermia)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Kaposi sarcoma (Goedert 2002), leukocytosis, petechia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, hepatomegaly, increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (Youssef 2016), sterile abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Postinjection flare (intraarticular)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Amyotrophy, apathy (Ciriaco 2013; Warrington 2006), depression (Ciriaco 2013; Warrington 2006), emotional lability, euphoria, headache, increased intracranial pressure (with papilledema), insomnia, malaise, myasthenia, neuritis, neuropathy, paresthesia, personality changes, psychiatric disturbance (including agitation, anxiety, distractibility, euphoria, fear, hypomania, insomnia, irritability, labile mood, lethargy, pressured speech, restlessness, tearfulness) (Ciriaco 2013; Warrington 2006), seizure, tingling of skin, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Buckley 2018), Charcot arthropathy, lipotrophy, myopathy (Liu 2013), osteonecrosis (femoral and humoral heads) (Liu 2013), osteoporosis (Buckley 2018, Leonard 2007), rupture of tendon (especially rupture of Achilles tendon), steroid myopathy (Haran 2018), vertebral compression fracture (Buckley 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blindness, glaucoma (Phulke 2017), increased intraocular pressure (Phulke 2017), subcapsular posterior cataract (Phulke 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound healing impairment</p></div>
<div class="block coi drugH1Div" id="F195365"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to methylprednisolone or any component of the formulation; systemic fungal infection (except intra-articular injection for localized joint conditions); intrathecal administration; live or attenuated virus vaccines (with immunosuppressive doses of corticosteroids); use in premature infants (formulations containing benzyl alcohol preservative only); immune thrombocytopenia (formerly known as idiopathic thrombocytopenic purpura) (IM administration only).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindication: Methylprednisolone sodium succinate 40 mg vial only: Hypersensitivity to cow's milk or its components or other dairy products which may contain trace amounts of milk ingredients (known or suspected).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling):</p>
<p style="text-indent:-2em;margin-left:4em;">Methylprednisolone tablets: Herpes simplex of the eye, vaccinia and varicella (except for short-term or emergency therapy)</p>
<p style="text-indent:-2em;margin-left:4em;">Methylprednisolone acetate injection: Epidural or intravascular administration; intra-articular injections in unstable joints; herpes simplex of the eye, vaccinia and varicella (except for short-term or emergency therapy)</p>
<p style="text-indent:-2em;margin-left:4em;">Methylprednisolone sodium succinate: Epidural administration; herpes simplex keratitis, vaccinia and varicella, arrested tuberculosis, acute psychoses, Cushing syndrome, peptic ulcer, markedly elevated serum creatinine (except for short-term or emergency therapy)</p></div>
<div class="block war drugH1Div" id="F195346"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: High doses of methylprednisolone IV (usually doses of 1 g/day in adults) may induce a toxic form of acute hepatitis (rare); serious hepatic injury may occur, resulting in acute liver failure and death. Time to onset can be several weeks or longer; resolution has been observed after discontinuation of therapy. Discontinue methylprednisolone if toxic hepatitis occurs. Avoid use of high doses in patients with a history of methylprednisolone-induced toxic hepatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Septic arthritis: May occur as a complication to parenteral therapy; institute appropriate antimicrobial therapy as required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart failure (HF) and/or hypertension; use has been associated with fluid retention, electrolyte disturbances, and hypertension. Use with caution following acute myocardial infarction (MI); corticosteroids have been associated with myocardial rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis, abscess or other pyogenic infection) due to perforation risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may cause transient worsening of myasthenia gravis (MG) (eg, within first 2 weeks of treatment); monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Septic shock or sepsis syndrome: Corticosteroids should not be administered for the treatment of sepsis in the absence of shock (SCCM/ESICM [Annane 2017]). A study has failed to demonstrate efficacy in septic shock or sepsis syndrome treatment; use may increase mortality in some populations (eg, patients with elevated serum creatinine, patients who develop secondary infections after use).</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic sclerosis (scleroderma): Use of higher dose corticosteroid therapy (in adults, ≥15 mg/day of prednisone or equivalent) in patients with systemic sclerosis may increase the risk of scleroderma renal crisis; avoid use when possible (Steen 1998; Trang 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults with the smallest possible effective dose for the shortest duration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May affect growth velocity; growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Methylprednisolone <b>acetate</b> IM injection (multiple-dose vial) and the diluent for methylprednisolone <b>sodium succinate</b> injection may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997], CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. Additionally, benzyl alcohol may also be toxic to neural tissue when administered locally (eg, intra-articular, intralesional). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epidural injection: Corticosteroids are not approved for epidural injection. Serious neurologic events (eg, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, stroke), some resulting in death, have been reported with epidural injection of corticosteroids, with and without use of fluoroscopy.</p></div>
<div class="block foc drugH1Div" id="F195358"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">P-Care D40: 40 mg/mL [DSC] [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">P-Care D80: 40 mg/mL [DSC] [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SOLU-Medrol: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg (1 ea); 125 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SOLU-Medrol: 40 mg (1 ea) [contains lactose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SOLU-Medrol: 125 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea); 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Injection, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DEPO-Medrol: 20 mg/mL (5 mL); 40 mg/mL (5 mL, 10 mL) [contains benzyl alcohol, polyethylene glycol (macrogol), polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DEPO-Medrol: 40 mg/mL (1 mL) [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DEPO-Medrol: 80 mg/mL (5 mL) [contains benzyl alcohol, polyethylene glycol (macrogol), polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DEPO-Medrol: 80 mg/mL (1 mL) [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg/mL (1 mL [DSC], 5 mL, 10 mL); 80 mg/mL (1 mL, 5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Injection, as acetate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">DEPO-Medrol: 40 mg/mL (1 mL) [contains polyethylene glycol (macrogol)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg/mL (1 mL); 80 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Medrol: 2 mg, 8 mg, 16 mg, 32 mg [DSC], 4 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mg, 16 mg, 32 mg, 4 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Medrol: 4 mg (21 ea) [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg (21 ea)</p></div>
<div class="block geq drugH1Div" id="F195342"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F195368"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (methylPREDNISolone Sodium Succ Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $4.90 - $7.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $7.75 - $13.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $26.40 - $27.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $39.00 - $50.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (SOLU-Medrol (PF) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $7.76</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg (per each): $12.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $56.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $82.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (SOLU-Medrol Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $124.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $29.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $52.78</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (DEPO-Medrol Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $8.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $13.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/mL (per mL): $23.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (methylPREDNISolone Acetate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/mL (per mL): $11.56 - $11.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg/mL (per mL): $19.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (Medrol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $0.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (methylPREDNISolone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $1.43 - $1.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Medrol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $1.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $0.37</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $2.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16 mg (per each): $3.45</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (methylPREDNISolone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $1.43 - $2.23</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $2.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">16 mg (per each): $3.11 - $3.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">32 mg (per each): $4.62 - $5.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867535"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SOLU-Medrol (PF): 40 mg (1 ea) [contains lactose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SOLU-Medrol (PF): 125 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sodium succinate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Solu-MEDROL: 500 mg (1 ea); 1000 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg (1 ea); 500 mg (1 ea); 1000 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Injection, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depo-Medrol: 20 mg/mL (5 mL) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depo-Medrol: 40 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depo-Medrol: 40 mg/mL (2 mL, 5 mL) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depo-Medrol: 80 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Depo-Medrol: 80 mg/mL (5 mL) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg/mL ([DSC]); 80 mg/mL ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Medrol: 16 mg, 4 mg</p></div>
<div class="block adip drugH1Div" id="F53567714"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Sodium content of 1 g sodium succinate injection: 2.01 mEq; methylprednisolone sodium succinate 53 mg = methylprednisolone base 40 mg</p></div>
<div class="block admp drugH1Div" id="F52613311"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer after meals or with food or milk to decrease GI upset. If prescribed once daily, administer dose in the early morning to mimic the normal diurnal variation of endogenous cortisol.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: <b>Acetate, succinate:</b> Avoid injection into the deltoid muscle due to a high incidence of subcutaneous atrophy. Avoid injection or leakage into the dermis. Do not inject into areas that have evidence of acute local infection. Discard contents of single-dose vial after use.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: <b>Succinate:</b></p>
<p style="text-indent:-2em;margin-left:6em;">IV push: May administer as a slow IV injection. Recommended rates range from over several minutes (dose not specified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>)) to over at least 5 minutes for doses ≤250 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.2'])">Ref</a></span>). Also refer to institution-specific policies and procedures.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent IV infusion: Rate dependent upon dose and severity of condition; typically administered as an intermittent infusion over 15 to 60 minutes. Administer doses &gt;250 mg over at least 30 to 60 minutes; severe adverse effects, including hypotension, cardiac arrhythmia, and sudden death, have been reported in patients receiving methylprednisolone doses ≥250 mg administered over &lt;30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2892818','lexi-content-ref-2690471','lexi-content-ref-10074612','lexi-content-ref-8217541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2892818','lexi-content-ref-2690471','lexi-content-ref-10074612','lexi-content-ref-8217541'])">Ref</a></span>). Pulse doses of 15 to 30 mg/kg used in rheumatic or kidney diseases in pediatric patients have been infused over 1 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15523124','lexi-content-ref-15322892','lexi-content-ref-17876609','lexi-content-ref-20108003','lexi-content-ref-27806747']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15523124','lexi-content-ref-15322892','lexi-content-ref-17876609','lexi-content-ref-20108003','lexi-content-ref-27806747'])">Ref</a></span>). Also refer to institution-specific policies and procedures. <b>Do not administer acetate form IV.</b></p></div>
<div class="block adm drugH1Div" id="F195362"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer tablets after meals or with food or milk to decrease GI upset. If prescribed once daily, administer in the morning.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM (acetate, succinate):</b> Avoid injection into the deltoid muscle due to a high incidence of subcutaneous atrophy. Avoid injection or leakage into the dermis. Do not inject into areas that have evidence of acute local infection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV (succinate):</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV push: May administer as a slow IV injection. Recommended rates range from over several minutes (dose not specified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>)) to over at least 5 minutes for doses ≤250 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.2'])">Ref</a></span>). Also refer to institution-specific policies and procedures.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: Rate dependent upon dose and severity of condition; typically administered as an intermittent infusion over 15 to 60 minutes. Administer doses &gt;250 mg over at least 30 to 60 minutes; severe adverse effects, including hypotension, cardiac arrhythmia, and sudden death, have been reported in patients receiving methylprednisolone doses ≥250 mg administered over &lt;30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2892818','lexi-content-ref-2690471','lexi-content-ref-10074612','lexi-content-ref-8217541']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2892818','lexi-content-ref-2690471','lexi-content-ref-10074612','lexi-content-ref-8217541'])">Ref</a></span>). Also refer to institution-specific policies and procedures. <b>Note:</b> In some spinal cord injury trials, bolus doses (30 mg/kg) have been administered over 15 minutes. <b>Do not administer acetate form IV.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-articular or soft tissue (acetate):</b> See manufacturer's labeling for details.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intralesional:</b> Inject directly into the lesion. For large lesions, administer multiple small injections (20 to 40 mg) into the area of the lesion. Avoid injection of sufficient material to cause blanching because this may be followed by a small slough.</p></div>
<div class="block sts drugH1Div" id="F195375"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Methylprednisolone acetate injection and tablets: Store at 20°C to 25°C (68°F to 77°F). Do not autoclave vials.</p>
<p style="text-indent:-2em;margin-left:2em;">Methylprednisolone sodium succinate injection: Store intact vials at 20°C to 25°C (68°F to 77°F). Protect from light. Do not autoclave. Store reconstituted vials at 20°C to 25°C (68°F to 77°F) and use within 48 hours. When further diluted with D5W, NS, or D5NS, may store at ≤25°C (77°F) for up to 4 hours or at 2°C to 8°C (36°F to 46°F) for up to 24 hours.</p></div>
<div class="block usep drugH1Div" id="F53567816"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Systemic: Oral, IM (acetate or succinate), IV (succinate only): Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases including those of hematologic (eg, immune thrombocytopenia [oral and IV only]), allergic, inflammatory, GI (eg, ulcerative colitis), ophthalmic, neoplastic, nervous system (eg, acute exacerbations of multiple sclerosis [oral and succinate (IV/IM) only]), renal (eg, nephrotic syndrome), respiratory (eg, asthma), rheumatic (eg, rheumatoid arthritis [juvenile idiopathic arthritis], systemic lupus erythematosus), and/or autoimmune origin (FDA approved in ages &gt;1 month and adults); has also been used for acute spinal cord injury, Kawasaki disease, <i>Pneumocystis</i> pneumonia, multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2, and prevention and treatment of graft-versus-host disease following allogeneic bone marrow transplantation.</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Depot formulations (Depo-Medrol): (FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">Intra-articular (or soft tissue) (acetate only): Gout (acute flare), acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and/or synovitis of osteoarthritis.</p>
<p style="text-indent:-2em;margin-left:4em;">Intralesional (acetate only): Alopecia areata; discoid lupus erythematosus; infiltrated, inflammatory lesions associated with granuloma annulare, lichen planus, neurodermatitis, and psoriatic plaques; keloids; necrobiosis lipoidica diabeticorum; may be helpful in cystic tumors of an aponeurosis or tendon (ganglia).</p></div>
<div class="block mst drugH1Div" id="F195438"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MethylPREDNISolone may be confused with medroxyPROGESTERone, methotrexate, methylTESTOSTERone, predniSONE</p>
<p style="text-indent:-2em;margin-left:4em;">DEPO-Medrol may be confused with Depo-Provera, SOLU-Medrol</p>
<p style="text-indent:-2em;margin-left:4em;">Medrol may be confused with Mebaral</p>
<p style="text-indent:-2em;margin-left:4em;">SOLU-Medrol may be confused with salmeterol, Solu-CORTEF</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Medrol [US, Canada, and multiple international markets] may be confused with Medral brand name for omeprazole [Mexico]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F195422"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F195351"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Abrocitinib.  Management: The use of abrocitinib in combination with other immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: Corticosteroids (Systemic) may diminish the therapeutic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of systemic corticosteroid is reduced. Corticosteroids (Systemic) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May increase the serum concentration of MethylPREDNISolone. Management: Decrease oral methylprednisolone dose by 50%, and decrease intravenous methylprednisolone dose by 25%, with aprepitant. No dose adjustment is required when used with only a single 40 mg oral dose or 32 mg injectable dose of aprepitant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Baricitinib.  Management: The use of baricitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Corticosteroids (Systemic) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Corticosteroids (Systemic) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CAR-T Cell Immunotherapy: Corticosteroids (Systemic) may enhance the adverse/toxic effect of CAR-T Cell Immunotherapy. Specifically, the severity and duration of neurologic toxicities may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of CAR-T Cell Immunotherapy.  Management: Avoid use of corticosteroids as premedication before treatment with CAR-T cell immunotherapy agents. Corticosteroids are indicated and may be required for treatment of toxicities such as cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Corticosteroids (Systemic) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing systemic corticosteroids (dosed at 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks) several weeks prior to coccidioides immitis skin antigen testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticorelin: Corticosteroids (Systemic) may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Corticosteroids (Systemic) may diminish the diagnostic effect of Cosyntropin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters)<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the neuroexcitatory and/or seizure-potentiating effect of MethylPREDNISolone. MethylPREDNISolone may decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of MethylPREDNISolone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of MethylPREDNISolone. Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of MethylPREDNISolone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of MethylPREDNISolone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and systemic corticosteroids. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: The use of deucravacitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Etrasimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Filgotinib.  Management: Coadministration of filgotinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: May increase the serum concentration of MethylPREDNISolone. Management: Decrease the oral methylprednisolone dose by 50%, and decrease the intravenous methylprednisolone dose by 25%, when combined with fosaprepitant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 Dotatate: Corticosteroids (Systemic) may diminish the diagnostic effect of Gallium Ga 68 Dotatate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Corticosteroids (Systemic) may diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Corticosteroids (Systemic) may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Corticosteroids (Systemic) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).  Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiation of systemic corticosteroids at immunosuppressive doses. Influenza vaccines administered less than 14 days prior to or during such therapy should be repeated 3 months after therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lutetium Lu 177 Dotatate: Corticosteroids (Systemic) may diminish the therapeutic effect of Lutetium Lu 177 Dotatate.  Management: Avoid repeated use of high-doses of corticosteroids during treatment with lutetium Lu 177 dotatate. Use of corticosteroids is still permitted for the treatment of neuroendocrine hormonal crisis. The effects of lower corticosteroid doses is unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Corticosteroids (Systemic) may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (eg, for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of MethylPREDNISolone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Corticosteroids (Systemic). Specifically, the risk of gastrointestinal bleeding, ulceration, and perforation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ozanimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Corticosteroids (Systemic) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Polymethylmethacrylate. Specifically, the risk for hypersensitivity or implant clearance may be increased.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Corticosteroids (Systemic) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Corticosteroids (Systemic) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing immunosuppressants, such as systemic corticosteroids, prior to initiating sipuleucel-T therapy. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone given for 2 or more weeks are immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Corticosteroids (Systemic) may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Corticosteroids (Systemic) may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Corticosteroids (Systemic) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Upadacitinib.  Management: Coadministration of upadacitinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone &gt; 2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines 4 weeks prior to therapy if possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Corticosteroids (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F195369"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take tablets with meals to decrease GI upset; need diet rich in pyridoxine, vitamin C, vitamin D, folate, calcium, phosphorus, and protein. </p></div>
<div class="block rep_considerations drugH1Div" id="F55466300"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Corticosteroids do not decrease fertility in patients with inflammatory bowel disease (IBD) who wish to become pregnant; however, active IBD may decrease fertility; pregnancy should be planned after a 3- to 6-month remission (Mahadevan 2019).</p></div>
<div class="block pri drugH1Div" id="F6472614"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Methylprednisolone crosses the placenta (Anderson 1981). Some products contain benzyl alcohol, which may also cross the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; however, information is conflicting and may be influenced by maternal dose, duration/frequency of exposure, and indication for use. Additional data are needed to evaluate any potential risk of systemic corticosteroids and other adverse pregnancy outcomes (eg, gestational diabetes mellitus, low birth weight, preeclampsia, preterm birth) (ACOG 776 2019; Bandoli 2017; Skuladottir 2014). Hypoadrenalism may occur in newborns following maternal use of corticosteroids; monitor infants exposed to prolonged or high doses of methylprednisolone in utero (Homar 2008; Kurtoğlu 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Methylprednisolone is a preferred oral corticosteroid for the treatment of maternal conditions during pregnancy because placental enzymes limit passage to the embryo (ACOG 776 2019).</p>
<p style="text-indent:0em;margin-top:2em;">When systemic corticosteroids are needed in pregnancy for rheumatic disorders, nonfluorinated corticosteroids such as methylprednisolone are preferred. Chronic high doses should be avoided (ACR [Sammaritano 2020]). Methylprednisolone may also be used to treat acute exacerbations of multiple sclerosis during pregnancy (Canibaño 2020; Dobson 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Corticosteroids may be used as needed for disease flares in pregnant patients with inflammatory bowel disease; however, maintenance therapy should be avoided (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes). Maternal asthma symptoms should be monitored monthly during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; however, systemic corticosteroids should be used to control acute exacerbations or treat severe persistent asthma (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Methylprednisolone may be considered for adjunctive treatment of severe nausea and vomiting in pregnant patients. Due to risks of adverse fetal events associated with first trimester exposure, use is reserved for refractory cases in women with dehydration (ACOG 189 2018).</p>
<p style="text-indent:0em;margin-top:2em;">High dose methylprednisolone may be used in the management of immune thrombocytopenia in pregnant patients refractory to oral corticosteroids; use in combination with other therapies is suggested (Provan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Systemic corticosteroids are used off label in the management of COVID-19 (NIH 2023). Methylprednisolone was not the corticosteroid evaluated in the initial study and large numbers of pregnant patients were not included (Horby 2021). In general, the treatment of COVID-19 during pregnancy is the same as in nonpregnant patients. However, because data for most therapeutic agents in pregnant patients are limited, treatment options should be evaluated as part of a shared decision-making process (NIH 2023). Patients who do not require corticosteroids for other indications, or in those who have already completed a course of corticosteroids to enhance fetal lung development, equivalent doses of methylprednisolone may be preferred for use in pregnant patients with severe or critical COVID-19 due to limited placental transfer and less fetal risk. Suggested treatment algorithms are available for pregnant patients with severe or critical COVID-19 requiring corticosteroids (Saad 2020; Teelucksingh 2022). The risk of severe illness from COVID-19 infection is increased in symptomatic pregnant patients compared to nonpregnant patients (ACOG 2023). Information related to the treatment of COVID-19 during pregnancy continues to emerge; refer to current guidelines for the treatment of pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">The Transplant Pregnancy Registry International (TPR) is a registry that follows pregnancies that occur in maternal transplant recipients or those fathered by male transplant recipients. The TPR encourages reporting of pregnancies following solid organ transplant by contacting them at 1-877-955-6877 or https://www.transplantpregnancyregistry.org.</p></div>
<div class="block mopp drugH1Div" id="F53567802"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, serum glucose, electrolytes, hemoglobin, occult blood loss, and clinical presence of adverse effects. Monitor intraocular pressure (if therapy &gt;6 weeks), bone mineral density (long-term use), and weight; growth in pediatric patients (with chronic use); assess hypothalamic-pituitary-adrenal axis (HPA) suppression.</p></div>
<div class="block pha drugH1Div" id="F195345"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">In a tissue-specific manner, corticosteroids regulate gene expression subsequent to binding specific intracellular receptors and translocation into the nucleus. Corticosteroids exert a wide array of physiologic effects including modulation of carbohydrate, protein, and lipid metabolism and maintenance of fluid and electrolyte homeostasis. Moreover cardiovascular, immunologic, musculoskeletal, endocrine, and neurologic physiology are influenced by corticosteroids. Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability.</p></div>
<div class="block phk drugH1Div" id="F195364"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV (succinate): Within 1 hour; Intra-articular (acetate): 1 week</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Intra-articular (acetate): 1 to 5 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed (Czock 2005)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 88% ± 23% (Czock 2005)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: IV (succinate): 24 L ± 6 L (Czock 2005)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to metabolites (Czock 2005)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IV: 1.9 ± 0.7 hours (age range: 12 to 20 years; Rouster-Stevens 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oral: 2.5 ± 1.2 hours (Czock 2005); IV (succinate): 0.25 ± 0.1 hour (Czock 2005)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 2.1 ± 0.7 hours (Czock 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">IV (succinate): 0.8 hours (Czock 2005)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (1.3% [oral], 9.2% [IV succinate] as unchanged drug) (Czock 2005)</p></div>
<div class="block phksp drugH1Div" id="F51159493"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Decreased clearance and increased half-life (Czock 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">Obesity: Decreased clearance and increased half-life (Czock 2005; Dunn 1991).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F195370"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Metilprednisolona | Metilprednisolona Pharmavial | Solu medrol | Totalsolona</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Metasol | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Methylpred | Methylprednisol sodium succinate | Methylprednisolone | Methylprednisolone alphapharm | Solu medrol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Depodrol | Depomed | Melpred | Mepcort | Methigic | Methipred | Methsolon | Predixa | Solupred</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Methylprednisolone | Methylprednisolone mayne pharma (ben) | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Mp | Solu medrol</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Methylprednisolon | Methylprednisolone sopharma | Methylprednisolone tchaikapharma | Solu medrol | Sophazolon | Urbason</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alergolon | Metilprednisolona | Predmetil | Solu medrol | Solupred | Solupren | Succinato sodico de metilpredinisolona | Succinato sodico de metilprednisolona | Unimedrol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Solu medrol | Solu moderin | Urbason | Urbason retard mite</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Mp | Prebien | Solu medrol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Solu medrol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Mei le song | Mi le song | Solu medrol | Urbason | You jin | You mi le</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aurompss | Cipridanol | Depo medrol | Medrol | Metilprednisolona | Precort | Solu medrol | Sumitric</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Methylprednisolone hikma | Metypred | Promedrol | Solu medrol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">M-Prednihexal | Medrate | Methylprednisolon | Methylprednisolon acis | Methylprednisolon hikma | Methylprednisolut | Metycortin | Metypred | Metypred GALEN | Metysolon | Predni m | Urbason | Urbason retard | Urbason retard mite | Urbason solub</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Solu medrol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Metilprednisolona | Solu medrol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Metypred | Solomet | Solu medrol</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | M.P.A | Methylprednisolone merck | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Depo moderin | Metilprednisol normon | Solu moderin | Urbason</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ciropred</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Medirona | Medrol | Solomet | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Methylprednisolone dakota | Methylprednisolone Dci | Methylprednisolone merck | Solumedrol</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Depo medrone | Medrone | Methylprednisolone | Solu medrone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Lyo Drol | Medrol | Provist | Solu medrol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Solu medrol</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Solu medrol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Lemod Solu | Medrol | Methylprednisolone sopharma | Metilprednizolon-h | Metilprednizolon-Human | Metypred | Solu medrol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Camelon | Comedrol | Cortesa | Ersolon | Flason | Fumethyl | Gamesolone | Glomeson | Hexilon | Iflaz | Indrol | Intidrol | Lameson | Lexcomet | Mecosolon | Medixon | Medrol | Meproson | Mesol | Metcor | Methylon | Methylprednisolone | Metidrol | Metisol | Metrison | Nichomedson | Ometilson | Phadilon | Prednicort | Prednox | Pretilon | Prolon | Rhemafar | Sanexon | Solu medrol | Somerol | Sonicor | Stenirol | Thimelon | Tisolon | Tison | Tropidrol | Urbason | Yalone</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Medrone | Solu medrone</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Solu medrol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acto pred | Alpred | Alptrela | Azipred | Blumeth | Bypride | Cartipred | Celopred | Coelone | Cortipred | Delsone m | Deposet | Depotex | Ecopred | Elcort m | Emcort | Ethislone | Imicort | Itisolon m | Ivepred | Lyopred | M proud | Macpred | Medea | Medrol | Mega pred | Melpred | Melsone | Mepdrol | Mepred | Mepresso | Mepresso t | Mepsonate | Methnilon | Methone | Methpred | Methyl Pred | Mp | Mpsol | Mpss | Mypred | Neo-drol | Nicort | Nucort m | Olsolone m | Onasolone | Pilsone | Praschamp | Prdlin | Predict m | Predmet | Prednosis | Prelid | Preylon | Pridz | Rapimedrol | Sanipred | Sodipred | Solipred | Solu cort | Solu medrol | Solupred | Spinopred | Sterio | Succimed | Succimed-O | Zempred</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Asmacortone | Cortrium | Lisamethyle | Medrol | Metilbetasone | Metildrol | Metilprednisolone | Metilprednisolone hikma | Urbason</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Medrolone | Solu medrol</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Decacort | Medrol | Mepredron | Pridol alfresa | Pridol aventis | Sol melcort taisho | Sol-melcort | Solu medrol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Metrite | Solu medrol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anasol | Asolone | Bearsolone | Boryung methylprednisolone | Celkor | Dasolone | Depo medrol | Disolin | Disolrin | Dnknip methylprednisolone | Empysolon | Hu methyl | Husolone | Jesolon | Jw prednisolone | Kedisolone | Konisolone | L solone | Lesol | Maffron | Md | Medione | Medipresol | Mediron | Medisol | Medisolone | Medisolu | Medisone | Mediwon | Medlone | Mednin | Medrol | Medsolone | Melon | Menirone | Menisolon | Menisolone | Mephsol | Mepilone | Mepisolone | Meplone | Mepna | Mepre | Mepresol | Mepron | Mepsolone | Mepy | Mesolome | Mesolone | Methisol | Methisolron | Methisone | Methybon | Methyl | Methyld | Methylon | Methylone | Methylpidi | Methylsolone | Methyran | Methyreid | Methysol | Methysolone | Methyson | Metylon | Metyrol | Mipron | Misolone | Mloid | Mpd | Mpd l | Mpss | Msolone | Nisolone m | Pd | Pd one | Pdilone | Pred | Predi | Predisol | Premedrol | Prena | Presolone | Prond | Salon | Salon h9c | Samsung methylprednisolone | Selond | Solenilone | Sologen | Solu medrol | Somelon | Someron | Spolon | Withus methibone | Yumerol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Solu medrol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Lisamethyle | Medrol | Methylprednisolone | Methylprednisolone mylan | Mp 40 | Solu medrol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Lisamethyle | Lyo drol | Medrol | Methylprednisolon | Methylprednisolone sopharma | Metilprednisolona normon | Metypred | Prednol | Prednol l | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Solu medrol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Medrol a | Methylprednisolone | Metypred | Prednol | Prednol l | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Solumedrol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acenovar | Aspidgem | Codemin art | Disminona | Fhucitil | Medroltil | Metilprednis.gi | Metilprednis.gi le | Metilprednisolona | Metisona | Predlitem | Prednilem | Prednovare | Radilem | Rumaxoi | Solsolona | Solu medrol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medixon | Methylprednisolone | Solu pred | Vaxcel methylprednisolone</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Macpred</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Metypresol | Solu medrol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Medrol Orifarm | Medrone | Metylprednisolon aurora medical | Solu medrol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Methylprednisolone | Solu medrol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Meprel | Metapred | Metilprednisolona | Oxcarcheck | Sol u pred | Solu medrol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Adrena | Biprosolone 125 | Depo medrol | Medixon | Medrol | Mepresone | Metcort | Methylpred | Prednivex | Prednox | Solu medrol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Hy solone | Solomed | Solu medrol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Meprelon | Metypred | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">A-methapred | Depo medrol | Medrol | Meprolone unipak | Solu medrol</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Metilprednisolona | Solu medrol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cipridanol | Maxilona | Metilprednisolona dallas | Metilprednisolona imedic | Metilprednisolona nortelab | Metilprednisolona prosalud | Metilprednisolona richet | Zolone</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Advantan | Advantan Fatty | Depo-Medrol | Exenate | Medrol | Prednol | Solu-Medrol | Solu-Medrol Act-O-Vial | Zytan</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Ivepred | Lemod | Medrol | Methylprednisolone Nativ | Metipred | Metypred | Metypred orion | Solu medrol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Intidrol | Medrol | Medrolone | Meproson | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Methylprednisolon orion | Solu medrol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Metylprednizolon hikma | Metypred | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Medixon | Medrol | Methpred | Solu medrol | Somidex</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Methylprednisolone mylan | Mp | Solu medrol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cortipol | Depo medrol | Meticure | Precort | Prednol | Prednol l | Urbason</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">A-methapred | Belon | Beron | Bony | Excelin | Licolone | Medason | Medlin | Mednin | Meho | Melin | Melone | Menisone | Mep | Mepred | Mepron | Mepson | Mesurin | Methylone | Methylprednisolone | Meticort | Metisone | Prea | Shinming | Solu medrol | Urbason</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Methylprednisolon | Metipred | Metypred | Solu medrol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Sanexon | Solu medrol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cipridanol | Metilprednisolona | Solu medrol</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Depo medrol | Medrol | Metilprednisolona | Novacort | Prednicort | Solu medrol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Bestpred | Cadipredson | Creao | Domenol | Medexa | Menison | Mezidtan | Predsantyl | Tanametrol | Thylmedi | Tomethrol | Vacometrol | Vinsolon</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ap methylpred | Medrol | Metypresol | Solu medrol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Medrol | Solu medrol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12186608">
<a name="12186608"></a>Abraham E, Evans T. Corticosteroids and Septic Shock [editorial]. <i>JAMA.</i> 2002;288(7):886-887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12186608/pubmed" id="12186608" target="_blank">12186608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16827597">
<a name="16827597"></a>Adams A, MacDermott EJ, Lehman TJ. Pharmacotherapy of lupus nephritis in children: a recommended treatment approach. <i>Drugs</i>. 2006;66(9):1191-1207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/16827597/pubmed" id="16827597" target="_blank">16827597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akahosi.1">
<a name="Akahosi.1"></a>Akahoshi S, Hasegawa Y. Steroid-induced iatrogenic adrenal insufficiency in children: a literature review. <i>Endocrines</i>. 2020;1(2):125-137. doi:10.3390/endocrines1020012</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17308245">
<a name="17308245"></a>Akikusa JD, Feldman BM, Gross GJ, Silverman ED, Schneider R. Sinus bradycardia after intravenous pulse methylprednisolone. <i>Pediatrics</i>. 2007;119(3):e778-782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/17308245/pubmed" id="17308245" target="_blank">17308245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hashash.1">
<a name="Hashash.1"></a>Al Hashash J, Regueiro M. Medical management of moderate to severe Crohn disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12870721">
<a name="12870721"></a>Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. <i>Sarcoidosis Vasc Diffuse Lung Dis</i>. 2003;20(2):118-125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12870721/pubmed" id="12870721" target="_blank">12870721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). What is the case definition of multisystem inflammatory syndrome in children (MIS-C)? Updated November 15, 2021. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266076">
<a name="29266076"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. <i>Obstet Gynecol</i>. 2018;131(1):e15-e30. doi:10.1097/AOG.0000000000002456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/29266076/pubmed" id="29266076" target="_blank">29266076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913201">
<a name="30913201"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 776: Immune modulating therapies in pregnancy and lactation. <i>Obstet Gynecol.</i> 2019;133(4):e287-e295. doi:10.1097/AOG.0000000000003176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/30913201/pubmed" id="30913201" target="_blank">30913201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACOG.1">
<a name="ACOG.1"></a>American College of Obstetricians and Gynecologists (ACOG). COVID-19 FAQs for obstetrician-gynecologists, obstetrics. https://www.acog.org/clinical-information/physician-faqs/covid-19-faqs-for-ob-gyns-obstetrics. Accessed April 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published January 2021. Accessed June 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12368690">
<a name="12368690"></a>Ancona KG, Parker RI, Atlas MP, Prakash D. Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children. <i>J Pediatr Hematol Oncol</i>. 2002;24(7):540-544. doi:10.1097/00043426-200210000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12368690/pubmed" id="12368690" target="_blank">12368690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7020419">
<a name="7020419"></a>Anderson GG, Rotchell Y, Kaiser DG. Placental Transfer of Methylprednisolone Following Maternal Intravenous Administration. <i>Am J Obstet Gynecol.</i> 1981;140(6):699-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/7020419/pubmed" id="7020419" target="_blank">7020419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28938253">
<a name="28938253"></a>Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. <i>Crit Care Med</i>. 2017;45(12):2078-2088. doi:10.1097/CCM.0000000000002737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28938253/pubmed" id="28938253" target="_blank">28938253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20581019">
<a name="20581019"></a>Aragon E, Chan YH, Ng KH, Lau YW, Tan PH, Yap HK. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. <i>Lupus</i>. 2010;19(8):965-973. doi:10.1177/0961203310366855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20581019/pubmed" id="20581019" target="_blank">20581019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arnold.1">
<a name="Arnold.1"></a>Arnold DM, Cuker A, Kelton JG. Initial treatment of immune thrombocytopenia (ITP) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 8, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Asero.1">
<a name="Asero.1"></a>Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17514629">
<a name="17514629"></a>Bahat E, Akkaya BK, Akman S, Karpuzoglu G, Guven AG. Comparison of pulse and oral steroid in childhood membranoproliferative glomerulonephritis. <i>J Nephrol</i>. 2007;20(2):234-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/17514629/pubmed" id="17514629" target="_blank">17514629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23090580">
<a name="23090580"></a>Baldwin D, Apel J. Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes. <i>Curr Diab Rep</i>. 2013;13(1):114-120. doi:10.1007/s11892-012-0339-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23090580/pubmed" id="23090580" target="_blank">23090580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28711148">
<a name="28711148"></a>Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. <i>Rheum Dis Clin North Am.</i> 2017;43(3):489-502. doi:10.1016/j.rdc.2017.04.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28711148/pubmed" id="28711148" target="_blank">28711148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28476259">
<a name="28476259"></a>Barniol C, Dehours E, Mallet J, Houze-Cerfon CH, Lauque D, Charpentier S. Levocetirizine and prednisone are not superior to levocetirizine alone for the treatment of acute urticaria: a randomized double-blind clinical trial. <i>Ann Emerg Med</i>. 2018;71(1):125-131.e1. doi:10.1016/j.annemergmed.2017.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28476259/pubmed" id="28476259" target="_blank">28476259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7045314">
<a name="7045314"></a>Barron KS, Person DA, Brewer EJ Jr, Beale MG, Robson AM. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. <i>J Pediatr</i>. 1982;101(1):137-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/7045314/pubmed" id="7045314" target="_blank">7045314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20656187">
<a name="20656187"></a>Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. <i>Transfus Med Rev</i>. 2010;24(3):195-210. doi:10.1016/j.tmrv.2010.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20656187/pubmed" id="20656187" target="_blank">20656187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34297684">
<a name="34297684"></a>Bartalena L, Kahaly GJ, Baldeschi L, et al; EUGOGO †. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.<i> Eur J Endocrinol</i>. 2021;185(4):G43-G67. doi:10.1530/EJE-21-0479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34297684/pubmed" id="34297684" target="_blank">34297684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23038682">
<a name="23038682"></a>Bartalena L, Krassas GE, Wiersinga W, et al; European Group on Graves' Orbitopathy. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. <i>J Clin Endocrinol Metab</i>. 2012;97(12):4454-4463. doi:10.1210/jc.2012-2389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23038682/pubmed" id="23038682" target="_blank">23038682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28191596">
<a name="28191596"></a>Basu B, Roy B, Babu BG. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. <i>Pediatr Nephrol</i>. 2017;32(6):1013-1021. doi:10.1007/s00467-017-3583-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28191596/pubmed" id="28191596" target="_blank">28191596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34140301">
<a name="34140301"></a>Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. <i>Eur Respir J.</i> 2021;58(6):2004079. doi:10.1183/13993003.04079-2020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34140301/pubmed" id="34140301" target="_blank">34140301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15841069">
<a name="15841069"></a>Benson CA, Kaplan JE, Masur H, et al. Treating Opportunistic Infections Among HIV-Exposed and Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health and the HIV Medicine Association/IDSA. <i>MMWR Recomm Rep.</i> 2004;53(RR-15):1-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15841069/pubmed" id="15841069" target="_blank">15841069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24766875">
<a name="24766875"></a>Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. <i>J Allergy Clin Immunol</i>. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/24766875/pubmed" id="24766875" target="_blank">24766875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17982350">
<a name="17982350"></a>Berris KK, Repp AL, Kleerekoper M. Glucocorticoid-induced osteoporosis. <i>Curr Opin Endocrinol Diabetes Obes</i>. 2007;14(6):446-450. doi:10.1097/MED.0b013e3282f15407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/17982350/pubmed" id="17982350" target="_blank">17982350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IDSA.2020">
<a name="IDSA.2020"></a>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Disease Society of America (IDSA), Guidelines on the treatment and management of patients with COVID-19. Published April 11, 2020. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Updated June 29, 2022. Accessed August 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29530386">
<a name="29530386"></a>Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review. <i>Diabetes Res Clin Pract</i>. 2018;139:203-220. doi:10.1016/j.diabres.2018.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/29530386/pubmed" id="29530386" target="_blank">29530386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8239251">
<a name="8239251"></a>Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. <i>Ann Intern Med</i>. 1993;119(12):1198-1208. doi:10.7326/0003-4819-119-12-199312150-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/8239251/pubmed" id="8239251" target="_blank">8239251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28649909">
<a name="28649909"></a>Boz C, Terzi M, Zengin Karahan S, Sen S, Sarac Y, Emrah Mavis M. Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis. <i>Mult Scler</i>. 2018;24(9):1205-1211. doi:10.1177/1352458517717806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28649909/pubmed" id="28649909" target="_blank">28649909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2278545">
<a name="2278545"></a>Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. <i>N Engl J Med.</i> 1990;322(20):1405-1411.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/2278545/pubmed" id="2278545" target="_blank">2278545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1727165">
<a name="1727165"></a>Bracken MB, Shepard MJ, Collins WF Jr, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. <i>J Neurosurg</i>. 1992;76(1):23-31<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/1727165/pubmed" id="1727165" target="_blank">1727165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9817404">
<a name="9817404"></a>Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial. <i>J Neurosurg</i>. 1998;89(5):699-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/9817404/pubmed" id="9817404" target="_blank">9817404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34607912">
<a name="34607912"></a>Bradshaw MJ, Pawate S, Koth LL, Cho TA, Gelfand JM. Neurosarcoidosis: pathophysiology, diagnosis, and treatment. <i>Neurol Neuroimmunol Neuroinflamm</i>. 2021;8(6):e1084. doi:10.1212/NXI.0000000000001084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34607912/pubmed" id="34607912" target="_blank">34607912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26509049">
<a name="26509049"></a>Briot K, Roux C. Glucocorticoid-induced osteoporosis. <i>RMD Open</i>. 2015;1(1):e000014. doi:10.1136/rmdopen-2014-000014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/26509049/pubmed" id="26509049" target="_blank">26509049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586507">
<a name="30586507"></a>Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. <i>N Engl J Med</i>. 2018;379(26):2547-2556. doi:10.1056/NEJMcp1800214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/30586507/pubmed" id="30586507" target="_blank">30586507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36480280">
<a name="36480280"></a>Burch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. <i>Thyroid</i>. 2022;32(12):1439-1470. doi:10.1089/thy.2022.0251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/36480280/pubmed" id="36480280" target="_blank">36480280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Campbell.1">
<a name="Campbell.1"></a>Campbell RL, Kelso JM. Anaphylaxis: Emergency treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25466802">
<a name="25466802"></a>Campbell RL, Li JT, Nicklas RA, Sadosty AT; Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. <i>Ann Allergy Asthma Immunol</i>. 2014;113(6):599-608. doi: 10.1016/j.anai.2014.10.007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25466802/pubmed" id="25466802" target="_blank">25466802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32128285">
<a name="32128285"></a>Canibaño B, Deleu D, Mesraoua B, Melikyan G, Ibrahim F, Hanssens Y. Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations.<i> J Drug Assess</i>. 2020;9(1):20-36. doi:10.1080/21556660.2020.1721507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32128285/pubmed" id="32128285" target="_blank">32128285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27986133">
<a name="27986133"></a>Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: gastrointestinal and endocrinologic side effects. <i>J Am Acad Dermatol</i>. 2017;76(1):11-16. doi:10.1016/j.jaad.2016.02.1239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27986133/pubmed" id="27986133" target="_blank">27986133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33204386">
<a name="33204386"></a>Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. <i>World Allergy Organ J</i>. 2020;13(10):100472. doi:10.1016/j.waojou.2020.100472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/33204386/pubmed" id="33204386" target="_blank">33204386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12152964">
<a name="12152964"></a>Cardone DA, Tallia AF. Joint and soft tissue injection. <i>Am Fam Physician</i>. 2002;66(2):283-288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12152964/pubmed" id="12152964" target="_blank">12152964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2648927">
<a name="2648927"></a>Carithers RL Jr, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. <i>Ann Intern Med.</i> 1989;110(9):685-690.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/2648927/pubmed" id="2648927" target="_blank">2648927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20307721">
<a name="20307721"></a>Carpenter PA, Macmillan ML, "Management of Acute Graft-Versus-Host Disease in Children," <i>Pediatr Clin North Am</i>, 2010, 57(1):273-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20307721/pubmed" id="20307721" target="_blank">20307721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23537669">
<a name="23537669"></a>Carroll CL, Sala KA. Pediatric status asthmaticus. <i>Crit Care Clin</i>. 2013;29(2):153-166. doi:10.1016/j.ccc.2012.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23537669/pubmed" id="23537669" target="_blank">23537669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Castells.1">
<a name="Castells.1"></a>Castells MC, Matulonis UA, Horton TM. Infusion reactions to systemic chemotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33557873">
<a name="33557873"></a>Cattalini M, Taddio A, Bracaglia C, et al. Childhood multisystem inflammatory syndrome associated with COVID-19 (MIS-C): a diagnostic and treatment guidance from the Rheumatology Study Group of the Italian Society of Pediatrics. <i>Ital J Pediatr</i>. 2021;47(1):24. doi:10.1186/s13052-021-00980-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/33557873/pubmed" id="33557873" target="_blank">33557873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.1">
<a name="Cattran.1"></a>Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34279063">
<a name="34279063"></a>Chalhoub NE, Wenderfer SE, Levy DM, et al. International consensus for the dosing of corticosteroids in childhood-onset systemic lupus erythematosus with proliferative lupus nephritis. <i>Arthritis Rheumatol</i>. Published online July 19, 2021. doi:10.1002/art.41930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34279063/pubmed" id="34279063" target="_blank">34279063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28566197">
<a name="28566197"></a>Chapelon-Abric C, Sene D, Saadoun D, et al. Cardiac sarcoidosis: diagnosis, therapeutic management and prognostic factors. <i>Arch Cardiovasc Dis</i>. 2017;110(8-9):456-465. doi:10.1016/j.acvd.2016.12.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28566197/pubmed" id="28566197" target="_blank">28566197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15525844">
<a name="15525844"></a>Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. <i>Medicine (Baltimore).</i> 2004;83(6):315-334. doi:10.1097/01.md.0000145367.17934.75<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15525844/pubmed" id="15525844" target="_blank">15525844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32463092">
<a name="32463092"></a>Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series. <i>J Pediatric Infect Dis Soc</i>. 2020;9(3):393-398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32463092/pubmed" id="32463092" target="_blank">32463092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24347992">
<a name="24347992"></a>Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervous system side effects. <i>J Pharmacol Pharmacother</i>. 2013;4(suppl 1):S94-S98. doi:10.4103/0976-500X.120975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/24347992/pubmed" id="24347992" target="_blank">24347992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33211859">
<a name="33211859"></a>Clouser KN, Gadhavi J, Bhavsar SM, et al. Short term outcomes after MIS-C treatment. <i>J Pediatric Infect Dis Soc</i>. Published online November 19, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/33211859/pubmed" id="33211859" target="_blank">33211859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25838326">
<a name="25838326"></a>Colvin MM, Cook JL, Chang P, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; et al. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;131(18):1608-1639.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25838326/pubmed" id="25838326" target="_blank">25838326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594318">
<a name="12594318"></a>Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. <i>N Engl J Med</i>. 2003;348(8):727-734. doi: 10.1056/NEJMra020529.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12594318/pubmed" id="12594318" target="_blank">12594318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25691380">
<a name="25691380"></a>Cooper SD, Felkins K, Baker TE, Hale TW. Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis. <i>J Hum Lact</i>. 2015;31(2):237-239.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25691380/pubmed" id="25691380" target="_blank">25691380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20643330">
<a name="20643330"></a>Costanzo MR, Dipchand A, Starling R, et al. International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. <i>J Heart Lung Transplant.</i> 2010;29(8):914-956. doi: 10.1016/j.healun.2010.05.034.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20643330/pubmed" id="20643330" target="_blank">20643330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24417307">
<a name="24417307"></a>Currò N, Covelli D, Vannucchi G, et al. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. <i>Thyroid</i>. 2014;24(5):897-905. doi:10.1089/thy.2013.0445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/24417307/pubmed" id="24417307" target="_blank">24417307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15634032">
<a name="15634032"></a>Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. <i>Clin Pharmacokinet</i>. 2005;44(1):61-98. doi:10.2165/00003088-200544010-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15634032/pubmed" id="15634032" target="_blank">15634032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21365201">
<a name="21365201"></a>Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. <i>Curr Treat Options Neurol</i>. 2011;13(3):311-323. doi: 10.1007/s11940-011-0119-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/21365201/pubmed" id="21365201" target="_blank">21365201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20371504">
<a name="20371504"></a>Dasgupta B, Borg FA, Hassan N, et al; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. <i>Rheumatology (Oxford)</i>. 2010;49(8):1594-1597. doi: 10.1093/rheumatology/keq039a.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20371504/pubmed" id="20371504" target="_blank">20371504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Davenport.1">
<a name="Davenport.1"></a>Davenport MS, Newhouse JH. Patient evaluation prior to oral or iodinated intravenous contrast for computed tomography. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30928086">
<a name="30928086"></a>Delaleu J, Destere A, Hachon L, Declèves X, Lloret-Linares C. Glucocorticoids dosing in obese subjects: a systematic review. <i>Therapie</i>. 2019;74(4):451-458. doi:10.1016/j.therap.2018.11.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/30928086/pubmed" id="30928086" target="_blank">30928086</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Depo-Medrol multi-dose vials (methylprednisolone acetate) [prescribing information]. New York, NY: Pfizer; June 2021.</div>
</li>
<li>
<div class="reference">
                  Depo-Medrol single-dose vials (methylprednisolone acetate) [prescribing information]. New York, NY: Pfizer; received June 2021.</div>
</li>
<li>
<div class="reference">
                  Depo-Medrol (methylprednisolone acetate) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22290637">
<a name="22290637"></a>DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(7):1001-1010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22290637/pubmed" id="22290637" target="_blank">22290637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9464184">
<a name="9464184"></a>Dickerson JE Jr, Dotzel E, Clark AF. Steroid-induced cataract: new perspective from in vitro and lens culture studies. <i>Exp Eye Res</i>. 1997;65(4):507-516. doi:10.1006/exer.1997.0359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/9464184/pubmed" id="9464184" target="_blank">9464184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21666852">
<a name="21666852"></a>Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. <i>Expert Rev Clin Pharmacol</i>. 2011;4(2):233-242. doi:10.1586/ecp.11.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/21666852/pubmed" id="21666852" target="_blank">21666852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31223468">
<a name="31223468"></a>Dineen R, Thompson CJ, Sherlock M. Adrenal crisis: prevention and management in adult patients. <i>Ther Adv Endocrinol Metab</i>. 2019;10:2042018819848218. doi:10.1177/2042018819848218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/31223468/pubmed" id="31223468" target="_blank">31223468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2892818">
<a name="2892818"></a>Ditzian-Kadanoff R, Ellman MH. How safe is it? High dose intravenous methylprednisolone. <i>IMJ Ill Med J</i>. 1987;172(6):432-434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/2892818/pubmed" id="2892818" target="_blank">2892818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22241902">
<a name="22241902"></a>Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. <i>Ann Rheum Dis</i>. 2012;71(7):1128-1133. doi:10.1136/annrheumdis-2011-200702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22241902/pubmed" id="22241902" target="_blank">22241902</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines. <i>Pract Neurol.</i> 2019;19(2):106-114. doi:10.1136/practneurol-2018-002060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/30612100/pubmed" id="30612100" target="_blank">30612100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21234507">
<a name="21234507"></a>Donatti TL, Koch VH, Takayama L, Pereira RM. Effects of glucocorticoids on growth and bone mineralization. <i>J Pediatr (Rio J)</i>. 2011;87(1):4-12. doi:10.2223/JPED.2052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/21234507/pubmed" id="21234507" target="_blank">21234507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24943696">
<a name="24943696"></a>Drozdowicz LB, Bostwick JM. Psychiatric adverse effects of pediatric corticosteroid use. <i>Mayo Clin Proc</i>. 2014;89(6):817-834. doi:10.1016/j.mayocp.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/24943696/pubmed" id="24943696" target="_blank">24943696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1827621">
<a name="1827621"></a>Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. <i>Clin Pharmacol Ther</i>. 1991;49(5):536-549. doi:10.1038/clpt.1991.64<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/1827621/pubmed" id="1827621" target="_blank">1827621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24980425">
<a name="24980425"></a>Dupuis S, Amiel JA, Desgroseilliers M, et al. Corticosteroids in the management of brain-dead potential organ donors: a systematic review. <i>Br J Anaesth</i>. 2014;113(3):346-359. doi: 10.1093/bja/aeu154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/24980425/pubmed" id="24980425" target="_blank">24980425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27007482">
<a name="27007482"></a>Durel CA, Marignier R, Maucort-Boulch D, et al. Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients. <i>J Neurol.</i> 2016;263(5):981-990. doi:10.1007/s00415-016-8092-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27007482/pubmed" id="27007482" target="_blank">27007482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29173297">
<a name="29173297"></a>Ebato T, Ogata S, Ogihara Y, et al. The clinical utility and safety of a new strategy for the treatment of refractory Kawasaki Disease. <i>J Pediatr</i>. 2017;191:140-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/29173297/pubmed" id="29173297" target="_blank">29173297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14625670">
<a name="14625670"></a>Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. <i>Intensive Care Med</i>. 2004;30(1):18-32. doi: 10.1007/s00134-003-2059-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/14625670/pubmed" id="14625670" target="_blank">14625670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2690471">
<a name="2690471"></a>Erstad BL. Severe cardiovascular adverse effects in association with acute, high-dose corticosteroid administration. <i>DICP</i>. 1989;23(12):1019-1023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/2690471/pubmed" id="2690471" target="_blank">2690471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32220834">
<a name="32220834"></a>Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Ann Rheum Dis</i>. 2020;79(6):713-723. doi:10.1136/annrheumdis-2020-216924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32220834/pubmed" id="32220834" target="_blank">32220834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fanta.1">
<a name="Fanta.1"></a>Fanta CH, Cahill KN. Acute exacerbations of asthma in adults: Emergency department and inpatient management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22764363">
<a name="22764363"></a>Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. <i>Am J Psychiatry</i>. 2012;169(5):491-497. doi:10.1176/appi.ajp.2011.11071009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22764363/pubmed" id="22764363" target="_blank">22764363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34472360">
<a name="34472360"></a>Fazelpour S, Sadek MM, Nery PB, et al. Corticosteroid and immunosuppressant therapy for cardiac sarcoidosis: a systematic review. <i>J Am Heart Assoc.</i> 2021;10(17):e021183. doi:10.1161/JAHA.121.021183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34472360/pubmed" id="34472360" target="_blank">34472360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fervenza.1">
<a name="Fervenza.1"></a>Fervenza FC, Leise MD, Roccatello D, Kyle RA. Mixed cryoglobulinemia syndrome: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31945371">
<a name="31945371"></a>Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. <i>Gastroenterology</i>. 2020;158(5):1450-1461. doi:10.1053/j.gastro.2020.01.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/31945371/pubmed" id="31945371" target="_blank">31945371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25641317">
<a name="25641317"></a>Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. <i>Muscle Nerve</i>. 2015;51(5):638-656. doi: 10.1002/mus.24566.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25641317/pubmed" id="25641317" target="_blank">25641317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32391934">
<a name="32391934"></a>FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. <i>Arthritis Care Res (Hoboken)</i>. 2020;72(6):744-760. doi:10.1002/acr.24180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32391934/pubmed" id="32391934" target="_blank">32391934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23298665">
<a name="23298665"></a>Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. <i>Diabetes Res Clin Pract</i>. 2013;99(3):277-280. doi:10.1016/j.diabres.2012.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23298665/pubmed" id="23298665" target="_blank">23298665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25399938">
<a name="25399938"></a>Forbess L, Bannykh S. Polyarteritis nodosa. <i>Rheum Dis Clin North Am</i>. 2015;41(1):33-46, vii. doi: 10.1016/j.rdc.2014.09.005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25399938/pubmed" id="25399938" target="_blank">25399938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furst.1">
<a name="Furst.1"></a>Furst DE, Saag KG. Determinants of glucocorticoid dosing. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furst.2">
<a name="Furst.2"></a>Furst DE, Saag KG. Glucocorticoid withdrawal. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gaffo.1">
<a name="Gaffo.1"></a>Gaffo AL. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21357821">
<a name="21357821"></a>García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. <i>Circulation</i>. 2011;123(10):1108-1115. doi:10.1161/CIRCULATIONAHA.110.973008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/21357821/pubmed" id="21357821" target="_blank">21357821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3792382">
<a name="3792382"></a>Garin EH, Sleasman JW, Richard GA, Iravani AA, Fennell RS. Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus nephritis. <i>Eur J Pediatr</i>. 1986;145(5):380-383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/3792382/pubmed" id="3792382" target="_blank">3792382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32956604">
<a name="32956604"></a>George MD, Baker JF, Winthrop K, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. <i>Ann Intern Med</i>. 2020;173(11):870-878. doi:10.7326/M20-1594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32956604/pubmed" id="32956604" target="_blank">32956604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10761200">
<a name="10761200"></a>Gereige RS, Barrios NJ. Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both. <i>P R Health Sci J</i>. 2000;19(1):15-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/10761200/pubmed" id="10761200" target="_blank">10761200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22187441">
<a name="22187441"></a>Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. <i>Diabetes Care</i>. 2012;35(1):181-188. doi:10.2337/dc11-1230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22187441/pubmed" id="22187441" target="_blank">22187441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23628833">
<a name="23628833"></a>Giuliano JS Jr, Faustino EV, Li S, et al. Corticosteroid therapy in critically ill pediatric asthmatic patients. <i>Pediatr Crit Care Med</i>. 2013;14(5):467-470. doi:10.1097/PCC.0b013e31828a7451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23628833/pubmed" id="23628833" target="_blank">23628833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Updated 2021. Accessed September 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2">
<a name="GINA.2"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD: 2023 report. https://goldcopd.org/2023-gold-report-2/. Accessed January 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12441327">
<a name="12441327"></a>Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst</i>. 2002;94(22):1712-1718. doi:10.1093/jnci/94.22.1712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12441327/pubmed" id="12441327" target="_blank">12441327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24507531">
<a name="24507531"></a>Goodin DS. Glucocorticoid treatment of multiple sclerosis. <i>Handb Clin Neurol</i>. 2014;122:455-464. doi: 10.1016/B978-0-444-52001-2.00020-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/24507531/pubmed" id="24507531" target="_blank">24507531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grissinger.1">
<a name="Grissinger.1"></a>Grissinger M. Medication errors: mix-ups with “medrols.” <i>P T</i>. 2007;32(8):417-419. https://www.ptcommunity.com/system/files/pdf/ptj3208417.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28877866">
<a name="28877866"></a>Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. <i>Ann Rheum Dis</i>. 2017;76(12):1965-1973. doi:10.1136/annrheumdis-2017-211898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28877866/pubmed" id="28877866" target="_blank">28877866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10074612">
<a name="10074612"></a>Guillén EL, Ruíz AM, Bugallo JB. Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient. <i>Am J Kidney Dis</i>. 1998;32(2):E4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/10074612/pubmed" id="10074612" target="_blank">10074612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32778886">
<a name="32778886"></a>Gupta A, Gill A, Sharma M, Garg M. Multi-system inflammatory syndrome in a child mimicking Kawasaki disease. <i>J Trop Pediatr</i>. Published online August 10, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32778886/pubmed" id="32778886" target="_blank">32778886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23919213">
<a name="23919213"></a>Guslandi M. Steroid ulcers: any news? <i>World J Gastrointest Pharmacol Ther</i>. 2013;4(3):39-40. doi:10.4292/wjgpt.v4.i3.39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23919213/pubmed" id="23919213" target="_blank">23919213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462474">
<a name="29462474"></a>Haran M, Schattner A, Kozak N, Mate A, Berrebi A, Shvidel L. Acute steroid myopathy: a highly overlooked entity. <i>QJM</i>. 2018;111(5):307-311. doi:10.1093/qjmed/hcy031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/29462474/pubmed" id="29462474" target="_blank">29462474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15523124">
<a name="15523124"></a>Hari P, Bagga A, Mantan M. Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. <i>Indian Pediatr</i>. 2004;41(10):993-1000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15523124/pubmed" id="15523124" target="_blank">15523124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35118829">
<a name="35118829"></a>Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology (ACR) clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: Version 3. <i>Arthritis Rheumatol</i>. Published online February 3, 2022. doi:10.1002/art.42062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/35118829/pubmed" id="35118829" target="_blank">35118829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28780657">
<a name="28780657"></a>Hogan J, Godron A, Baudouin V, et al. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. <i>Pediatr Nephrol</i>. 2018;33(1):111-116. doi:10.1007/s00467-017-3767-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28780657/pubmed" id="28780657" target="_blank">28780657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18784429">
<a name="18784429"></a>Homar V, Grosek S, Battelino T. High-dose methylprednisolone in a pregnant woman with Crohn's disease and adrenal suppression in her newborn. <i>Neonatology</i>. 2008;94(4):306-309. doi:10.1159/000151652<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/18784429/pubmed" id="18784429" target="_blank">18784429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25471548">
<a name="25471548"></a>Honoré PM, Jacobs R, De Waele E, et al. What do we know about steroids metabolism and 'PK/PD approach' in AKI and CKD especially while on RRT--current status in 2014.<i> Blood Purif</i>. 2014;38(2):154-157. doi:10.1159/000368390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25471548/pubmed" id="25471548" target="_blank">25471548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15850848">
<a name="15850848"></a>Hopkins RL, Leinung MC. Exogenous Cushing's syndrome and glucocorticoid withdrawal. <i>Endocrinol Metab Clin North Am</i>. 2005;34(2):371-ix. doi:10.1016/j.ecl.2005.01.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15850848/pubmed" id="15850848" target="_blank">15850848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32678530">
<a name="32678530"></a>Horby P, Lim WS, Emberson JR, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. <i>N Engl J Med</i>. 2021;384(8):693-704. doi:10.1056/NEJMoa2021436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32678530/pubmed" id="32678530" target="_blank">32678530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30715219">
<a name="30715219"></a>Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors.<i> Cardiovasc Res.</i> 2019;115(5):854-868. doi:10.1093/cvr/cvz026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/30715219/pubmed" id="30715219" target="_blank">30715219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23417182">
<a name="23417182"></a>Hurlbert RJ, Hadley MN, Walters BC, et al. Pharmacological therapy for acute spinal cord injury. <i>Neurosurgery</i>. 2013;72(suppl 2):93-105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23417182/pubmed" id="23417182" target="_blank">23417182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18684744">
<a name="18684744"></a>Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. <i>Ann Rheum Dis</i>. 2009;68(7):1119-1124. doi:10.1136/ard.2008.092163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/18684744/pubmed" id="18684744" target="_blank">18684744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practices (ISMP). Do not let “depo-" medications be a depot for mistakes. https://www.ismp.org/resources/do-not-let-depo-medications-be-depot-mistakes. Updated March 24, 2016. Accessed October 7, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081650">
<a name="28081650"></a>James C, Berstein JA. Current and future therapies for the treatment of histamine-induced angioedema. <i>Expert Opin Pharmacother</i>. 2017;18(3):253-262. doi: 10.1080/14656566.2017.1282461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28081650/pubmed" id="28081650" target="_blank">28081650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17900234">
<a name="17900234"></a>James ER. The etiology of steroid cataract. <i>J Ocul Pharmacol Ther</i>. 2007;23(5):403-420. doi:10.1089/jop.2006.0067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/17900234/pubmed" id="17900234" target="_blank">17900234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31656440">
<a name="31656440"></a>Janes M, Kuster S, Goldson TM, Forjuoh SN. Steroid-induced psychosis. <i>Proc (Bayl Univ Med Cent)</i>. 2019;32(4):614-615. doi:10.1080/08998280.2019.1629223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/31656440/pubmed" id="31656440" target="_blank">31656440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23546607">
<a name="23546607"></a>Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. <i>JAMA Intern Med.</i> 2013;1:1-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23546607/pubmed" id="23546607" target="_blank">23546607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33003176">
<a name="33003176"></a>Jonat B, Gorelik M, Boneparth A, et al. Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children's hospital in New York City: patient characteristics and an institutional protocol for evaluation, management, and follow-up. <i>Pediatr Crit Care Med</i>. 2021;22(3):e178-e191. doi:10.1097/PCC.0000000000002598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/33003176/pubmed" id="33003176" target="_blank">33003176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27105755">
<a name="27105755"></a>Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. <i>Semin Arthritis Rheum</i>. 2016;46(1):133-141. doi:10.1016/j.semarthrit.2016.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27105755/pubmed" id="27105755" target="_blank">27105755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15998777">
<a name="15998777"></a>Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. <i>J Clin</i>
<i>Endocrinol Metab</i>. 2005;90(9):5234-5240. doi:10.1210/jc.2005-0148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15998777/pubmed" id="15998777" target="_blank">15998777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024029">
<a name="23024029"></a>Khanna D, Khanna PP, Fitzgerald JD, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(10):1447-1461. doi:10.1002/acr.21773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23024029/pubmed" id="23024029" target="_blank">23024029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34556256">
<a name="34556256"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. <i>Kidney Int</i>. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34556256/pubmed" id="34556256" target="_blank">34556256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23485027">
<a name="23485027"></a>Kobayashi T, Kobayashi T, Morikawa A, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. <i>J Pediatr</i>. 2013;163(2):521-526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23485027/pubmed" id="23485027" target="_blank">23485027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22405251">
<a name="22405251"></a>Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. <i>Lancet</i>. 2012;379(9826):1613-1620.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22405251/pubmed" id="22405251" target="_blank">22405251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25978154">
<a name="25978154"></a>Kotloff RM, Blosser S, Fulda GJ, et al; Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Donor Management Task Force. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations consensus statement. <i>Crit Care Med</i>. 2015;43(6):1291-1325. doi: 10.1097/CCM.0000000000000958.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25978154/pubmed" id="25978154" target="_blank">25978154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21911331">
<a name="21911331"></a>Kurtoğlu S, Sarıcı D, Akın MA, Daar G, Korkmaz L, Memur Ş. Fetal adrenal suppression due to maternal corticosteroid use: case report. <i>J Clin Res Pediatr Endocrinol.</i> 2011;3(3):160-162. doi:10.4274/jcrpe.v3i3.31<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/21911331/pubmed" id="21911331" target="_blank">21911331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32036458">
<a name="32036458"></a>Lakatos P, Szili B, Bakos B, Takacs I, Putz Z, Istenes I. Thyroid hormones, glucocorticoids, insulin, and bone. <i>Handb Exp Pharmacol.</i> 2020;262:93-120. doi:10.1007/164_2019_314<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32036458/pubmed" id="32036458" target="_blank">32036458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15932528">
<a name="15932528"></a>Lam DS, Fan DS, Ng JS, Yu CB, Wong CY, Cheung AY. Ocular hypertensive and anti-inflammatory responses to different dosages of topical dexamethasone in children: a randomized trial. <i>Clin Exp Ophthalmol</i>. 2005;33(3):252-258. doi:10.1111/j.1442-9071.2005.01022.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15932528/pubmed" id="15932528" target="_blank">15932528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26135706">
<a name="26135706"></a>Le Page E, Veillard D, Laplaud DA, et al; COPOUSEP investigators; West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. <i>Lancet</i>. 2015;386(9997):974-981. doi: 10.1016/S0140-6736(15)61137-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/26135706/pubmed" id="26135706" target="_blank">26135706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17332238">
<a name="17332238"></a>Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. <i>Pediatrics</i>. 2007;119(suppl 2):S166-S174. doi:10.1542/peds.2006-2023J<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/17332238/pubmed" id="17332238" target="_blank">17332238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27057889">
<a name="27057889"></a>Leonhard SE, Fritz D, Eftimov F, van der Kooi AJ, van de Beek D, Brouwer MC. Neurosarcoidosis in a tertiary referral center: a cross-sectional cohort study. <i>Medicine (Baltimore)</i>. 2016;95(14):e3277. doi:10.1097/MD.0000000000003277<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27057889/pubmed" id="27057889" target="_blank">27057889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34709662">
<a name="34709662"></a>Li M, Wong D, Vogel AS, et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. <i>Hepatology</i>. 2022;75(3):531-540. doi:10.1002/hep.32215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34709662/pubmed" id="34709662" target="_blank">34709662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23947590">
<a name="23947590"></a>Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. <i>Allergy Asthma Clin Immunol</i>. 2013;9(1):30. doi:10.1186/1710-1492-9-30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23947590/pubmed" id="23947590" target="_blank">23947590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi: 10.1038/ajg.2018.27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26505932">
<a name="26505932"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol</i>. 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8217541">
<a name="8217541"></a>Lucas KG, Howrie DL, Phebus CK. Cardiorespiratory decompensation following methylprednisolone administration. <i>Pediatr Hematol Oncol</i>. 1993;10(3):249-255.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/8217541/pubmed" id="8217541" target="_blank">8217541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33611981">
<a name="33611981"></a>Lui JK, Mesfin N, Tugal D, Klings ES, Govender P, Berman JS. Critical care of patients with cardiopulmonary complications of sarcoidosis. <i>J Intensive Care Med.</i> 2022;37(4):441-458. doi:10.1177/0885066621993041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/33611981/pubmed" id="33611981" target="_blank">33611981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35579642">
<a name="35579642"></a>Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. <i>JAMA</i>. 2022;327(19):1888-1898. doi:10.1001/jama.2022.5368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/35579642/pubmed" id="35579642" target="_blank">35579642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18930568">
<a name="18930568"></a>Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. <i>Am J Kidney Dis</i>. 2009;53(1):26-32. doi:10.1053/j.ajkd.2008.07.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/18930568/pubmed" id="18930568" target="_blank">18930568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22511141">
<a name="22511141"></a>Macdonald PS, Aneman A, Bhonagiri D, et al. A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors. <i>Crit Care Med</i>. 2012;40(5):1635-1644. doi: 10.1097/CCM.0b013e3182416ee7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22511141/pubmed" id="22511141" target="_blank">22511141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31970405">
<a name="31970405"></a>Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology (Oxford)</i>. 2020;59(3):e1-e23. doi:10.1093/rheumatology/kez672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/31970405/pubmed" id="31970405" target="_blank">31970405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30658060">
<a name="30658060"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Gastroenterology</i>. 2019;156(5):1508-1524. doi:10.1053/j.gastro.2018.12.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/30658060/pubmed" id="30658060" target="_blank">30658060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19628647">
<a name="19628647"></a>Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. <i>Nephrol Dial Transplant</i>. 2009;24(12):3694-3701. doi:10.1093/ndt/gfp356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/19628647/pubmed" id="19628647" target="_blank">19628647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11502779">
<a name="11502779"></a>Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.<i> J Clin Endocrinol Metab</i>. 2001;86(8):3562-3567. doi:10.1210/jcem.86.8.7737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/11502779/pubmed" id="11502779" target="_blank">11502779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20222881">
<a name="20222881"></a>Marks SD and Tullus K, "Modern Therapeutic Strategies for Paediatric Systemic Lupus Erythematosus and Lupus Nephritis," <i>Acta Paediatr</i>, 2010, 99(7):967-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20222881/pubmed" id="20222881" target="_blank">20222881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22510384">
<a name="22510384"></a>Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. <i>Biol Blood Marrow Transplant</i>. 2012;18(8):1150-1163. doi: 10.1016/j.bbmt.2012.04.005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22510384/pubmed" id="22510384" target="_blank">22510384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23465020">
<a name="23465020"></a>Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. <i>Am J Transplant</i>. 2013;13(suppl 4):272-279. doi: 10.1111/ajt.12119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23465020/pubmed" id="23465020" target="_blank">23465020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mathes.1">
<a name="Mathes.1"></a>Mathes BM, Alguire PC. Intralesional corticosteroid injection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235884">
<a name="34235884"></a>Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and takayasu arteritis. <i>Arthritis Rheumatol</i>. 2021;73(8):1349-1365. doi:10.1002/art.41774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34235884/pubmed" id="34235884" target="_blank">34235884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23381030">
<a name="23381030"></a>Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. <i>Nat Rev Endocrinol</i>. 2013;9(5):265-276. doi:10.1038/nrendo.2013.5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23381030/pubmed" id="23381030" target="_blank">23381030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356445">
<a name="28356445"></a>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28356445/pubmed" id="28356445" target="_blank">28356445</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Medrol tablets (methylprednisolone) [prescribing information]. New York, NY: Pfizer; February 2019.</div>
</li>
<li>
<div class="reference">
                  Medrol (methylprednisolone) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17426195">
<a name="17426195"></a>Meduri G, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. <i>Chest</i>. 2007;131(4):954-963. doi: 10.1378/chest.06-2100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/17426195/pubmed" id="17426195" target="_blank">17426195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34143362">
<a name="34143362"></a>Melani AS, Bigliazzi C, Cimmino FA, Bergantini L, Bargagli E. A comprehensive review of sarcoidosis treatment for pulmonologists.<i> Pulm Ther.</i> 2021;7(2):325-344. doi:10.1007/s41030-021-00160-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34143362/pubmed" id="34143362" target="_blank">34143362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merkel.1">
<a name="Merkel.1"></a>Merkel PA. Treatment and prognosis of polyarteritis nodosa. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 12, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merkel.2">
<a name="Merkel.2"></a>Merkel PA. Treatment of Takayasu arteritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 26, 2022.</div>
</li>
<li>
<div class="reference">
                  Methylprednisolone tablets [prescribing information]. Peapack, NJ: Greenstone LLC; July 2012.</div>
</li>
<li>
<div class="reference">
                  Methylprednisolone injectable suspension [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; July 2019.</div>
</li>
<li>
<div class="reference">
                  Methylprednisolone injectable suspension [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; September 2020.</div>
</li>
<li>
<div class="reference">
                  Methylprednisolone injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; December 2016.</div>
</li>
<li>
<div class="reference">
                  Methylprednisolone injection [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25359357">
<a name="25359357"></a>Meyer KC, Raghu G, Verleden GM, et al; ISHLT/ATS/ERS BOS Task Force Committee; ISHLT/ATS/ERS BOS Task Force Committee. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. <i>Eur Respir J</i>. 2014;44(6):1479-1503.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25359357/pubmed" id="25359357" target="_blank">25359357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23982055">
<a name="23982055"></a>Migita K, Sasaki Y, Ishizuka N, et al. Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease. <i>Medicine (Baltimore)</i>. 2013;92(5):285-293. doi:10.1097/MD.0b013e3182a72299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23982055/pubmed" id="23982055" target="_blank">23982055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11835067">
<a name="11835067"></a>Milad MA, Ludwig EA, Lew KH, Kohli RK, Jusko WJ. The pharmacokinetics and pharmacodynamics of methylprednisolone in chronic renal failure. <i>Am J Ther.</i> 1994;1(1):49-57. doi:10.1097/00045391-199406000-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/11835067/pubmed" id="11835067" target="_blank">11835067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22162255">
<a name="22162255"></a>Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(3):375-383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/22162255/pubmed" id="22162255" target="_blank">22162255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18175148">
<a name="18175148"></a>Miura M, Kohno K, Ohki H, Yoshiba S, Sugaya A, Satoh M. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. <i>Eur J Pediatr</i>. 2008;167(10):1119-1123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/18175148/pubmed" id="18175148" target="_blank">18175148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15322892">
<a name="15322892"></a>Mori K, Honda M, Ikeda M. Efficacy of methylprednisolone pulse therapy in steroid-resistant nephrotic syndrome. <i>Pediatr Nephrol</i>. 2004;19(11):1232-1236. doi:10.1007/s00467-004-1584-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15322892/pubmed" id="15322892" target="_blank">15322892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27799164">
<a name="27799164"></a>Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. <i>Blood</i>. 2017;129(3):289-298. doi: 10.1182/blood-2016-09-719773.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27799164/pubmed" id="27799164" target="_blank">27799164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24909803">
<a name="24909803"></a>Muraro A, Roberts G, Worm M, et al; EAACI Food Allergy and Anaphylaxis Guidelines Group. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. <i>Allergy</i>. 2014;69(8):1026-1045. doi: 10.1111/all.12437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/24909803/pubmed" id="24909803" target="_blank">24909803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19566504">
<a name="19566504"></a>Myhr KM, Mellgren SI. Corticosteroids in the treatment of multiple sclerosis. <i>Acta Neurol Scand Suppl</i>. 2009;(189):73-80. doi: 10.1111/j.1600-0404.2009.01213.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/19566504/pubmed" id="19566504" target="_blank">19566504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27012010">
<a name="27012010"></a>Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27012010/pubmed" id="27012010" target="_blank">27012010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24833682">
<a name="24833682"></a>Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. <i>BMJ Open</i>. 2014;4(5):e004587. doi:10.1136/bmjopen-2013-004587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/24833682/pubmed" id="24833682" target="_blank">24833682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.1">
<a name="NAEPP.1"></a>National Asthma Education and Prevention Program (NAEPP). Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services; National Institutes of Health; National Heart Lung, and Blood Institute; 2007. <a href="http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" target="_blank">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a>. Published October 2007. Accessed June 15, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Institutes of Health (NIH). COVID-19 Treatment Guidelines Panel. Therapeutic management of hospitalized pediatric patients with multisystem inflammatory syndrome in children (MIS-C) (with discussion on multisystem inflammatory syndrome in adults [MIS-A]). <a href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/" target="_blank">https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-pediatric-patients--therapeutic-management-of-mis-c/</a>. Updated February 24, 2022a. Accessed March 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2020">
<a name="NIH.2020"></a>National Institutes of Health (NIH). Coronavirus disease (COVID-19) treatment guidelines: Therapeutic management of patients with COVID-19. <a href="https://www.covid19treatmentguidelines.nih.gov/therapeutic-management" target="_blank">https://www.covid19treatmentguidelines.nih.gov/therapeutic-management</a>. Updated September 26, 2022b. Accessed September 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.3">
<a name="NIH.3"></a>National Institutes of Health (NIH). Coronavirus disease (COVID-19) treatment guidelines: Therapeutic management of patients with COVID-19. <a href="https://www.covid19treatmentguidelines.nih.gov/therapeutic-management" target="_blank">https://www.covid19treatmentguidelines.nih.gov/therapeutic-management</a>. Updated April 20, 2023. Accessed May 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Multiple sclerosis in adults: management. Clinical guideline [CG186]. https://www.nice.org.uk/guidance/cg186. Published October 2014. Accessed October 7, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25905379">
<a name="25905379"></a>Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP. Glucocorticoid therapy and adrenal suppression. In: Feingold KR, Anawalt B, Boyce A, et al., eds. <i>Endotext</i>. MDText.com, Inc.; October 19, 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25905379/pubmed" id="25905379" target="_blank">25905379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26686437">
<a name="26686437"></a>Novitzky D, Mi Z, Collins JF, Cooper DK. Increased procurement of thoracic donor organs after thyroid hormone therapy. <i>Semin Thorac Cardiovasc Surg</i>. 2015;27(2):123-132. doi: 10.1053/j.semtcvs.2015.06.012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/26686437/pubmed" id="26686437" target="_blank">26686437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25405914">
<a name="25405914"></a>Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. <i>Transplantation</i>. 2014;98(10):1119-1127. doi: 10.1097/TP.0000000000000187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25405914/pubmed" id="25405914" target="_blank">25405914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Olek.1">
<a name="Olek.1"></a>Olek MJ, Howard J. Treatment of acute exacerbations of multiple sclerosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3998938">
<a name="3998938"></a>Ost L, Wettrell G, Bjorkhem I, et al. Prednisolone Excretion in Human Milk. <i>J Pediatr.</i> 1985;106(6):1008-1011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/3998938/pubmed" id="3998938" target="_blank">3998938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33523115">
<a name="33523115"></a>Ouldali N, Toubiana J, Antona D, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. <i>JAMA</i>. Published online February 1, 2021.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/33523115/pubmed" id="33523115" target="_blank">33523115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9596297">
<a name="9596297"></a>Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV <i>Pneumocystis carinii</i> pneumonia. <i>Chest.</i> 1998;113(5):1215-1224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/9596297/pubmed" id="9596297" target="_blank">9596297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19383611">
<a name="19383611"></a>Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. <i>QJM</i>. 2009;102(7):449-460. doi:10.1093/qjmed/hcp042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/19383611/pubmed" id="19383611" target="_blank">19383611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33923971">
<a name="33923971"></a>Pelewicz K, Miśkiewicz P. Glucocorticoid withdrawal—an overview on when and how to diagnose adrenal insufficiency in clinical practice. <i>Diagnostics (Basel)</i>. 2021;11(4):728. doi:10.3390/diagnostics11040728<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/33923971/pubmed" id="33923971" target="_blank">33923971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17876609">
<a name="17876609"></a>Peña A, Bravo J, Melgosa M, et al. Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy. <i>Pediatr Nephrol</i>. 2007;22(11):1875-1880. doi:10.1007/s00467-007-0567-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/17876609/pubmed" id="17876609" target="_blank">17876609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Peppercorn.1">
<a name="Peppercorn.1"></a>Peppercorn MA, Farrell RJ. Management of the hospitalized adult patient with severe colitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20471889">
<a name="20471889"></a>Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. <i>Joint Bone Spine</i>. 2011;78(1):41-44. doi:10.1016/j.jbspin.2010.02.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20471889/pubmed" id="20471889" target="_blank">20471889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34524933">
<a name="34524933"></a>Perlman DM, Sudheendra MT, Furuya Y, et al. Clinical presentation and treatment of high-risk sarcoidosis.<i> Ann Am Thorac Soc</i>. 2021;18(12):1935-1947. doi:10.1513/AnnalsATS.202102-212CME<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34524933/pubmed" id="34524933" target="_blank">34524933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28924342">
<a name="28924342"></a>Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced glaucoma: an avoidable irreversible blindness. <i>J Curr Glaucoma Pract</i>. 2017;11(2):67-72. doi:10.5005/jp-journals-l0028-1226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28924342/pubmed" id="28924342" target="_blank">28924342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27177728">
<a name="27177728"></a>Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. <i>Lancet Diabetes Endocrinol</i>. 2016;4(7):611-629. doi:10.1016/S2213-8587(16)00086-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27177728/pubmed" id="27177728" target="_blank">27177728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25711134">
<a name="25711134"></a>Powell RJ, Leech SC, Till S, et al; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. <i>Clin Exp Allergy</i>. 2015;45(3):547-565. doi: 10.1111/cea.12494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25711134/pubmed" id="25711134" target="_blank">25711134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10093981">
<a name="10093981"></a>Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. <i>Lancet</i>. 1999;353(9156):883-887. doi:10.1016/s0140-6736(98)03563-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/10093981/pubmed" id="10093981" target="_blank">10093981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34253540">
<a name="34253540"></a>Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. <i>BMJ</i>. 2021;374:n1380. doi:10.1136/bmj.n1380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34253540/pubmed" id="34253540" target="_blank">34253540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770441">
<a name="31770441"></a>Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Adv</i>. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/31770441/pubmed" id="31770441" target="_blank">31770441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27802508">
<a name="27802508"></a>Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. <i>Ann Intern Med</i>. 2017;166(1):58-68. doi:10.7326/M16-0570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27802508/pubmed" id="27802508" target="_blank">27802508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3068012">
<a name="3068012"></a>Raisz LG. Hormonal regulation of bone growth and remodelling. <i>Ciba Found Symp</i>. 1988;136:226-238. doi:10.1002/9780470513637.ch14<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/3068012/pubmed" id="3068012" target="_blank">3068012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21757964">
<a name="21757964"></a>Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. <i>Ophthalmic Res</i>. 2012;47(2):66-80. doi:10.1159/000328630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/21757964/pubmed" id="21757964" target="_blank">21757964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.2">
<a name="manu.2"></a>Refer to Canadian manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27457514">
<a name="27457514"></a>Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27457514/pubmed" id="27457514" target="_blank">27457514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roberts.1">
<a name="Roberts.1"></a>Roberts WN. Intraarticular and soft tissue injections: What agent(s) to inject and how frequently? Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 3, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12605114">
<a name="12605114"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. <i>Transplantation</i>. 2003a;75(4):482-487. doi:10.1097/01.TP.0000045683.85282.93<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12605114/pubmed" id="12605114" target="_blank">12605114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12717226">
<a name="12717226"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. <i>Transplantation</i>. 2003b;75(8):1336-1341. doi:10.1097/01.TP.0000062839.58826.6D<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12717226/pubmed" id="12717226" target="_blank">12717226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26034636">
<a name="26034636"></a>Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. <i>Neurooncol Pract</i>. 2015;2(1):6-12. doi:10.1093/nop/npu029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/26034636/pubmed" id="26034636" target="_blank">26034636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18240180">
<a name="18240180"></a>Rouster-Stevens KA, Gursahaney A, Ngai KL, et al. Pharmacokinetic Study of Oral Prednisolone Compared With Intravenous Methylprednisolone in Patients With Juvenile Dermatomyositis.<i> Arthritis Rheum.</i> 2008;59(2):222-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/18240180/pubmed" id="18240180" target="_blank">18240180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23157995">
<a name="23157995"></a>Roxanas MG, Hunt GE. Rapid reversal of corticosteroid-induced mania with sodium valproate: a case series of 20 patients. <i>Psychosomatics</i>. 2012;53(6):575-581. doi:10.1016/j.psym.2012.06.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23157995/pubmed" id="23157995" target="_blank">23157995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840605">
<a name="30840605"></a>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. <i>Am J Gastroenterol</i>. 2019;114(3):384-413. doi:10.14309/ajg.0000000000000152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/30840605/pubmed" id="30840605" target="_blank">30840605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23892326">
<a name="23892326"></a>Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN Working Group recommendations for a standardized practice. <i>Bone Marrow Transplant</i>. 2014;49(2):168-173. doi:10.1038/bmt.2013.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23892326/pubmed" id="23892326" target="_blank">23892326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32769659">
<a name="32769659"></a>Saad AF, Chappell L, Saade GR, Pacheco LD. Corticosteroids in the management of pregnant patients with coronavirus disease (COVID-19). <i>Obstet Gynecol</i>. 2020;136(4):823-826. doi:10.1097/AOG.0000000000004103<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32769659/pubmed" id="32769659" target="_blank">32769659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9790371">
<a name="9790371"></a>Safari HR, Fassett MJ, Souter IC, et al. The efficacy of methylprednisolone in the treatment of hyperemesis gravidarum: a randomized, double-blind, controlled study. <i>Am J Obstet Gynecol</i>. 1998;179(4):921-924.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/9790371/pubmed" id="9790371" target="_blank">9790371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Salvarani.1">
<a name="Salvarani.1"></a>Salvarani C, Muratore F. Treatment of giant cell arteritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology (ACR) guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sax.1">
<a name="Sax.1"></a>Sax PE. Treatment and prevention of <i>Pneumocystis</i> infection in patients with HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32001253">
<a name="32001253"></a>Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. <i>J Allergy Clin Immunol.</i> 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32001253/pubmed" id="32001253" target="_blank">32001253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20108003">
<a name="20108003"></a>Shenoy M, Plant ND, Lewis MA, Bradbury MG, Lennon R, Webb NJ. Intravenous methylprednisolone in idiopathic childhood nephrotic syndrome. <i>Pediatr Nephrol</i>. 2010;25(5):899-903. doi:10.1007/s00467-009-1417-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/20108003/pubmed" id="20108003" target="_blank">20108003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-854143">
<a name="854143"></a>Sherlock JE, Letteri JM. Effect of hemodialysis on methylprednisolone plasma levels. <i>Nephron</i>. 1977;18(4):208-211. doi:10.1159/000180830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/854143/pubmed" id="854143" target="_blank">854143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23268454">
<a name="23268454"></a>Simons FE, Ardusso LR, Bilò MB; World Allergy Organization. World Allergy Organization guidelines for the assessment and management of anaphylaxis. <i>World Allergy Organ J</i>. 2011;4(2):13-37. doi: 10.1097/WOX.0b013e318211496c.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23268454/pubmed" id="23268454" target="_blank">23268454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26525001">
<a name="26525001"></a>Simons FE, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. <i>World Allergy Organ J</i>. 2015;8(1):32. doi:10.1186/s40413-015-0080-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/26525001/pubmed" id="26525001" target="_blank">26525001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29336434">
<a name="29336434"></a>Singal AK, Bataller R, Ahn J, et al. ACG Clinical Guideline: alcoholic liver disease. <i>Am J Gastroenterol.</i> 2018;113(2):175-194. doi:10.1038/ajg.2017.469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/29336434/pubmed" id="29336434" target="_blank">29336434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23868909">
<a name="23868909"></a>Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Ann Rheum Dis</i>. 2014;73(2):328-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23868909/pubmed" id="23868909" target="_blank">23868909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777675">
<a name="24777675"></a>Skuladottir H, Wilcox AJ, Ma C, et al. Corticosteroid use and risk of orofacial clefts. <i>Birth Defects Res A Clin Mol Teratol.</i> 2014;100(6):499-506. doi:10.1002/bdra.23248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/24777675/pubmed" id="24777675" target="_blank">24777675</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Solu-Medrol (methylprednisolone sodium succinate) [prescribing information]. New York, NY: Pharmacia &amp; Upjohn Co; October 2021.</div>
</li>
<li>
<div class="reference">
                  Solu-Medrol and Solu-Medrol Act-O-Vials (methylprednisolone sodium succinate) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34133855">
<a name="34133855"></a>Son MBF, Murray N, Friedman K, et al; Overcoming COVID-19 Investigators. Multisystem inflammatory syndrome in children—initial therapy and outcomes. <i>N Engl J Med</i>. 2021;385(1)23-34. doi:10.1056/NEJMoa2102605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34133855/pubmed" id="34133855" target="_blank">34133855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30272171">
<a name="30272171"></a>Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(11):4043-4088. doi:10.1210/jc.2018-01865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/30272171/pubmed" id="30272171" target="_blank">30272171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9751093">
<a name="9751093"></a>Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. <i>Arthritis Rheum</i>. 1998;41(9):1613-1619.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/9751093/pubmed" id="9751093" target="_blank">9751093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29150328">
<a name="29150328"></a>Stein CA, Levin R, Given R, et al. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: the STAAR study. <i>Urol Oncol.</i> 2018;36(2):81.e9-81.e16. doi:10.1016/j.urolonc.2017.10.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/29150328/pubmed" id="29150328" target="_blank">29150328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16625008">
<a name="16625008"></a>Steinberg KP, Hudson LD, Goodman RB; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. <i>N Engl J Med</i>. 2006;354(16):1671-1684. doi:10.1056/NEJMoa051693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/16625008/pubmed" id="16625008" target="_blank">16625008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15167067">
<a name="15167067"></a>Stern BJ. Neurological complications of sarcoidosis.<i> Curr Opin Neurol.</i> 2004;17(3):311-316. doi:10.1097/00019052-200406000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/15167067/pubmed" id="15167067" target="_blank">15167067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stoller.1">
<a name="Stoller.1"></a>Stoller JK. COPD exacerbations: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25583837">
<a name="25583837"></a>Strijbos E, Coenradie S, Touw DJ, Aerden L. High-dose methylprednisolone for multiple sclerosis during lactation: concentrations in breast milk. <i>Mult Scler</i>. 2015;21(6):797-798.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25583837/pubmed" id="25583837" target="_blank">25583837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26240704">
<a name="26240704"></a>Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. <i>World J Diabetes</i>. 2015;6(8):1073-1081. doi:10.4239/wjd.v6.i8.1073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/26240704/pubmed" id="26240704" target="_blank">26240704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36337130">
<a name="36337130"></a>Teelucksingh S, Nana M, Nelson-Piercy C. Managing COVID-19 in pregnant women. <i>Breathe (Sheff)</i>. 2022;18(2):220019. doi:10.1183/20734735.0019-2022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/36337130/pubmed" id="36337130" target="_blank">36337130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33268456">
<a name="33268456"></a>Thillai M, Atkins CP, Crawshaw A, et al. BTS clinical statement on pulmonary sarcoidosis. <i>Thorax</i>. 2021;76(1):4-20. doi:10.1136/thoraxjnl-2019-214348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/33268456/pubmed" id="33268456" target="_blank">33268456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thomas.2019">
<a name="Thomas.2019"></a>Thomas CF Jr, Limper AH. Treatment and prevention of <i>Pneumocystis</i> infection in patients without HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21132302">
<a name="21132302"></a>Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. <i>Rheumatol Int</i>. 2012;32(3):645-653. doi:10.1007/s00296-010-1697-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/21132302/pubmed" id="21132302" target="_blank">21132302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32382828">
<a name="32382828"></a>Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. <i>Pediatr Nephrol</i>. 2020;35(8):1529-1561. doi:10.1007/s00467-020-04519-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32382828/pubmed" id="32382828" target="_blank">32382828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096497">
<a name="26096497"></a>Tseng CL, Chen YT, Huang CJ, et al. Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study. <i>Aliment Pharmacol Ther</i>. 2015;42(5):599-606. doi:10.1111/apt.13298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/26096497/pubmed" id="26096497" target="_blank">26096497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30044357">
<a name="30044357"></a>Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;67(2):257-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/30044357/pubmed" id="30044357" target="_blank">30044357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3541262">
<a name="3541262"></a>Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. <i>Surv Ophthalmol</i>. 1986;31(2):102-110. doi:10.1016/0039-6257(86)90077-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/3541262/pubmed" id="3541262" target="_blank">3541262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Updated November 18, 2021. Accessed December 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated March 19, 2021. Accessed December 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12733732">
<a name="12733732"></a>van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. <i>J Bone Miner Res</i>. 2003;18(5):913-918. doi:10.1359/jbmr.2003.18.5.913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/12733732/pubmed" id="12733732" target="_blank">12733732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19170748">
<a name="19170748"></a>Varron L, Broussolle C, Candessanche JP, et al. Spinal cord sarcoidosis: report of seven cases. <i>Eur J Neurol.</i> 2009;16(3):289-296. doi:10.1111/j.1468-1331.2008.02409.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/19170748/pubmed" id="19170748" target="_blank">19170748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34655742">
<a name="34655742"></a>Velentza L, Zaman F, Sävendahl L. Bone health in glucocorticoid-treated childhood acute lymphoblastic leukemia. <i>Crit Rev Oncol Hematol</i>. 2021;168:103492. doi:10.1016/j.critrevonc.2021.103492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34655742/pubmed" id="34655742" target="_blank">34655742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2449258">
<a name="2449258"></a>von dem Borne AE, Vos JJ, Pegels JG, Thomas LL, van der Lelie. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. <i>Br Med J (Clin Res Ed)</i>. 1988;296(6617):249-250. doi:10.1136/bmj.296.6617.249-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/2449258/pubmed" id="2449258" target="_blank">2449258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16117821">
<a name="16117821"></a>Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. <i>Clin Endocrinol (Oxf)</i>. 2005;63(3):323-328. doi:10.1111/j.1365-2265.2005.02345.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/16117821/pubmed" id="16117821" target="_blank">16117821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28836444">
<a name="28836444"></a>Wallace MD, Metzger NL. Optimizing the treatment of steroid-induced hyperglycemia. <i>Ann Pharmacother</i>. 2018;52(1):86-90. doi:10.1177/1060028017728297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/28836444/pubmed" id="28836444" target="_blank">28836444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17036562">
<a name="17036562"></a>Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. <i>Mayo Clin Proc</i>. 2006;81(10):1361-1367. doi:10.4065/81.10.1361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/17036562/pubmed" id="17036562" target="_blank">17036562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23137579">
<a name="23137579"></a>Winthrop KL. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. <i>Rheum Dis Clin North Am</i>. 2012;38(4):727-745. doi:10.1016/j.rdc.2012.08.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/23137579/pubmed" id="23137579" target="_blank">23137579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. https://apps.who.int/iris/handle/10665/62435.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2020">
<a name="WHO.2020"></a>World Health Organization (WHO). Corticosteroids for COVID-19: living guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. Published September 2, 2020. Accessed December 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8538233">
<a name="8538233"></a>Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. <i>Mayo Clin Proc</i>. 1996;71(1):5-13. doi:10.4065/71.1.5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/8538233/pubmed" id="8538233" target="_blank">8538233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19011472">
<a name="19011472"></a>Yildirim ZK, Büyükavci M, Eren S, Orbak Z, Sahin A, Karakelleoğlu C. Late side effects of high-dose steroid therapy on skeletal system in children with idiopathic thrombocytopenic purpura. <i>J Pediatr Hematol Oncol</i>. 2008;30(10):749-753. doi:10.1097/MPH.0b013e318180bbc9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/19011472/pubmed" id="19011472" target="_blank">19011472</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Yonsa (abiraterone acetate) [prescribing information]. Horsham, PA: Janssen Biotech Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29184808">
<a name="29184808"></a>Younes AK, Younes NK. Recovery of steroid induced adrenal insufficiency. <i>Transl Pediatr</i>. 2017;6(4):269-273. doi:10.21037/tp.2017.10.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/29184808/pubmed" id="29184808" target="_blank">29184808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3302924">
<a name="3302924"></a>Younger RE, Gerber PS, Herrod HG, Cohen RM, Crawford LV. Intravenous methylprednisolone efficacy in status asthmaticus of childhood. <i>Pediatrics</i>. 1987;80(2):225-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/3302924/pubmed" id="3302924" target="_blank">3302924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26611557">
<a name="26611557"></a>Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. <i>Rheum Dis Clin North Am</i>. 2016;42(1):157-x. doi:10.1016/j.rdc.2015.08.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/26611557/pubmed" id="26611557" target="_blank">26611557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25271314">
<a name="25271314"></a>Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. <i>Haematologica</i>. 2014;99(10):1547-1554. doi:10.3324/haematol.2014.114561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/25271314/pubmed" id="25271314" target="_blank">25271314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zeiser.1">
<a name="Zeiser.1"></a>Zeiser R. Treatment of acute graft-versus-host disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32768896">
<a name="32768896"></a>Zengin Karahan S, Boz C, Terzi M, et al. Methylprednisolone concentrations in breast milk and serum of patients with multiple sclerosis treated with IV pulse methylprednisolone. <i>Clin Neurol Neurosurg</i>. 2020;197:106118. doi:10.1016/j.clineuro.2020.106118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/32768896/pubmed" id="32768896" target="_blank">32768896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27806747">
<a name="27806747"></a>Zhang H, Wang Z, Dong LQ, Guo YN. Children with steroid-resistant nephrotic syndrome: long-term outcomes of sequential steroid therapy. <i>Biomed Environ Sci</i>. 2016;29(9):650-655. doi:10.3967/bes2016.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/27806747/pubmed" id="27806747" target="_blank">27806747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34536239">
<a name="34536239"></a>Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy</i>. 2022;77(3):734-766. doi:10.1111/all.15090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methylprednisolone-pediatric-drug-information/abstract-text/34536239/pubmed" id="34536239" target="_blank">34536239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zuraw.1">
<a name="Zuraw.1"></a>Zuraw B. An overview of angioedema: Clinical features, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 16, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12601 Version 653.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
